 eventide asset management llc acquires new position in vulcan materials company nysevmc  bnb daily daily ratings  news for vulcan materials company complete the form below to receive the latest headlines and analysts recommendationsfor vulcan materials company with our free daily email newsletter follow bnbdailynews recent posts eventide asset management llc acquires new position in vulcan materials company nysevmc driehaus capital management llc purchases new stake in versartis inc vsar western union company the nysewu shares bought by old mutual customised solutions proprietary ltd harleydavidson inc nysehog position held by laffer investments klatencor corporation nasdaqklac shares bought by janus capital management llc diplomat pharmacy inc nysedplo shares sold by janus capital management llc old mutual customised solutions proprietary ltd has  position in thomson reuters corp nysetri fny partners fund lp purchases new stake in dynegy inc nysedyn  shares in plexus corp nasdaqplxs acquired by gotham asset management llc cheniere energy inc nyselng shares bought by old mutual customised solutions proprietary ltd bluecrest capital management ltd acquires new position in first republic bank nysefrc tesoro logistics lp tllp shares bought by driehaus capital management llc driehaus capital management llc buys  shares of modine manufacturing company mod symantec corporation symc shares sold by oak associates ltd oh trust co of vermont has  million position in church  dwight company inc nysechd magellan midstream partners lp mmp cut to sell at zacks investment research crown castle international corporation nysecci raised to strongbuy at zacks investment research hennessy capital acquisition corp ii dske rating increased to hold at valuengine lear corporation nyselea downgraded by zacks investment research kapstone paper and packaging corporation nyseks upgraded at vertical research eventide asset management llc acquires new position in vulcan materials company nysevmc posted by dan jones on jul nd   no comments eventide asset management llc purchased a new stake in vulcan materials company nysevmc during the first quarter according to its most recent f filing with the securities and exchange commission sec the institutional investor purchased  shares of the construction company’s stock valued at approximately  eventide asset management llc owned about  of vulcan materials at the end of the most recent reporting period other institutional investors have also recently modified their holdings of the company gilder gagnon howe  co llc purchased a new position in shares of vulcan materials during the first quarter valued at about  alexandria capital llc increased its position in shares of vulcan materials by  in the first quarter alexandria capital llc now owns  shares of the construction company’s stock worth  after buying an additional  shares during the period next financial group inc increased its position in shares of vulcan materials by  in the first quarter next financial group inc now owns  shares of the construction company’s stock worth  after buying an additional  shares during the period barings llc bought a new position in shares of vulcan materials during the fourth quarter worth  finally independent advisor alliance bought a new position in shares of vulcan materials during the fourth quarter worth   of the stock is owned by hedge funds and other institutional investors vulcan materials company vmc traded up  during midday trading on friday hitting   shares of the stock traded hands the stock has a day moving average of  and a  day moving average of  vulcan materials company has a week low of  and a week high of  the firm has a market cap of  billion a pe ratio of  and a beta of  get vulcan materials company alerts vulcan materials nysevmc last announced its earnings results on wednesday may th the construction company reported  earnings per share eps for the quarter beating the zacks’ consensus estimate of  by  the company had revenue of  million for the quarter compared to analyst estimates of  million vulcan materials had a return on equity of  and a net margin of  vulcan materials’s quarterly revenue was up  on a yearoveryear basis during the same period in the prior year the company posted  eps equities analysts forecast that vulcan materials company will post  eps for the current year the company also recently declared a quarterly dividend which will be paid on friday september th investors of record on wednesday august rd will be given a dividend of  per share this represents a  annualized dividend and a dividend yield of  the exdividend date is monday august st vulcan materials’s dividend payout ratio is currently  copyright violation warning “eventide asset management llc acquires new position in vulcan materials company nysevmc” was originally published by bnb daily and is owned by of bnb daily if you are viewing this story on another site it was stolen and reposted in violation of us and international copyright  trademark law the legal version of this story can be accessed at httpswwwbaseballnewsblogcomeventideassetmanagementllcpurchasessharesofvulcanmaterialscompanyvmcupdatedupdatedhtml several research firms have weighed in on vmc bidaskclub downgraded shares of vulcan materials from a “hold” rating to a “sell” rating in a research report on wednesday july th zacks investment research raised shares of vulcan materials from a “hold” rating to a “buy” rating and set a  price objective for the company in a research note on tuesday june th royal bank of canada reissued a “buy” rating and issued a  price objective on shares of vulcan materials in a research note on monday june th argus increased their price objective on shares of vulcan materials from  to  and gave the stock a “buy” rating in a research note on friday june th finally citigroup inc reaffirmed a “buy” rating on shares of vulcan materials in a research note on thursday may th one analyst has rated the stock with a sell rating four have assigned a hold rating and six have assigned a buy rating to the company the stock currently has an average rating of “hold” and an average target price of  in other news vp ejaz a khan sold  shares of the company’s stock in a transaction on tuesday june th the stock was sold at an average price of  for a total value of  the sale was disclosed in a document filed with the securities  exchange commission which is accessible through the sec website also insider stanley g bass sold  shares of the company’s stock in a transaction on wednesday june th the shares were sold at an average price of  for a total value of  following the completion of the sale the insider now owns  shares of the company’s stock valued at approximately  the disclosure for this sale can be found here over the last three months insiders have sold  shares of company stock worth  corporate insiders own  of the company’s stock vulcan materials company profile vulcan materials company is a supplier of construction aggregates primarily crushed stone sand and gravel and a producer of asphalt mix and readymixed concrete the company operates through four segments aggregates asphalt mix concrete and calcium the aggregates segment produces and sells aggregates crushed stone sand and gravel sand and other aggregates and related products and services transportation and other receive news  ratings for vulcan materials company daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for vulcan materials company and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website eventide  q cio update read more eventide healthcare  life sciences fund named wsj category king for health  biotech read more eventide gilead fund read more eventide healthcare  life sciences fund read more eventide multiasset income fund read more gilead fund midcap growth focused  billion  since inception morningstar ★★★★ healthcare  life sciences fund smallcap healthcare  million  since inception morningstar ★★ multiasset income fund diversified income  million  since inception gilead fund a diversified equity mutual fund representing our “best ideas” that seeks to provide longterm capital appreciation historical emphases in small and midcap growth health care and information technology… read more creating true value eventide’s investment philosophy is rooted in the belief that companies that prosper best and sustainably are the ones that serve and in turn bless humankind… read more eventide cio updates eventide’s cio finny kuruvilla offers quarterly updates on funds as well as commentary on the world economy and financial markets investment professionals may contact us to request access eventide’s cio finny kuruvilla offers quarterly updates on funds as well as commentary on the world economy and financial markets… read more mutual funds involve risk including the possible loss of principal past performance does not guarantee future resultsthe funds’ ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria the funds can have risk related to option investing there are special risks associated with investments in foreign companies including exposure to currency fluctuations less efficient trading markets political instability and differing auditing and legal standards because of ongoing market volatility the funds performance may be subject to substantial shortterm changes the eventide gilead fund  eventide healthcare  life sciences fund can invest in smallersized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies the funds can also have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the us food and drug administration the funds can invest in private companies private investments include various risks including but not limited to lack of liquidity capital commitment risk and valuation risk private companies may not be financially profitable and have uncertain futures subjecting them to additional risks investors in the gilead fund should be aware that companies in the technology industries have different risks including but not limited to products becoming obsolete and entrance of competing products companies in the industrial sector also carry various risks including but not limited to risk related to debt loads and intense competition investors in the eventide multiasset income fund should be aware that interest rates are at historic lows and may change at any time based on government policy in general the price of a fixed income security falls when interest rates rise a rise in interest rates may result in volatility and increased redemptions which in turn could result in the fund being forced to liquidate portfolio securities at disadvantageous prices longerterm securities may be more sensitive to changes in interest rates the intermediateterm bond portion of the fund’s portfolio may represent  to  of the fund’s portfolio with an average duration of between two and eight years the eventide multiasset income fund may invest in other funds if other funds are utilized such underlying funds are subject to investment advisory and other expenses which will be indirectly paid by the fund as a result your cost of investing in the fund will be higher than the cost of investing directly in underlying funds and may be higher than other mutual funds that do not invest in underlying funds the fund may invest directly or indirectly in “junk bonds” such securities are speculative investments that carry greater risks than higher quality debt securities there are unique risks associated with reits mlps preferred stocks convertible bonds bdcs and yieldcos that are covered in the funds prospectus and sai the fund is a new mutual fund and has a limited history of operations for investors to evaluate an investor should consider a funds investment objectives risks charges and expenses carefully before investing or sending money this and other important information can be found in the prospectus which can be obtained at wwweventidefundscom or by calling even  please read the prospectus carefully before investing eventide mutual funds are distributed by northern lights distributors llc member finra which is not affiliated with eventide asset management llc nld eventide asset management llc private company information  bloomberg july    am et capital markets company overview of eventide asset management llc snapshot people company overview eventide asset management llc is a privately owned investment manager the firm primarily provides its services to investment companies it also caters to corporations and other businesses the firm manages client focused equity portfolios it also launches and manages equity mutual funds for its clients the firm invests in public equity market across the globe it typically invests in value stocks of companies the firm employs fundamental and technical analysis to make its investments it does biblically responsible investing and primarily invests in healthcare and life sciences sectors to create its portfolios the firm uses external and internal research to make its investments eventi eventide asset management llc is a privately owned investment manager the firm primarily provides its services to investment companies it also caters to corporations and other businesses the firm manages client focused equity portfolios it also launches and manages equity mutual funds for its clients the firm invests in public equity market across the globe it typically invests in value stocks of companies the firm employs fundamental and technical analysis to make its investments it does biblically responsible investing and primarily invests in healthcare and life sciences sectors to create its portfolios the firm uses external and internal research to make its investments eventide asset management llc was founded in april  and is based in boston massachusetts detailed description one international placesuite boston ma united statesfounded in  phone  fax  wwweventidefundscom key executives for eventide asset management llc mr robin cheriakalath john chief executive officer and managing partner mr david andrew barksdale chief financial officer managing partner and portfolio manager dr finny george kuruvilla md phd chief investment officer managing partner and portfolio manager age  mr jason lewis myhre managing partner and director of advisory services mr peter luiso chief compliance officer and general counsel compensation as of fiscal year  eventide asset management llc key developments eventide asset management hires peter luiso as chief compliance office and general counsel jun   eventide asset management llc announced that peter luiso an attorney and former vice president in asset management compliance at fidelity investments will join eventides growing team as chief compliance officer and general counsel peter brings to eventide an extensive background in securities regulation peter has served as the deputy cco of fidelitys strategic advisers funds and he joined eventide from his role as head of fidelitys compliance programs overseeing subadvisers and rias supporting mutual funds etfs and other advisory services eventide funds appoints jeff cave as head of distribution dec   eventide funds announced that jeff cave will lead its sales and distribution efforts as head of distribution mr cave will specifically lead sales and distribution to institutional channels and will continue to improve eventides quality of service to financial advisors and clients mr cave brings extensive experience from his prior role as an ultra high net worth uhnw wealth management specialist for the private banking and investment group at merrill lynch prior to joining eventide mr cave was with merrill lynch for almost  years most recently as director uhnw wealth management specialist for the private banking and investment group at merrill lynch based in new york city similar private companies by industry company name region visory llc united states  road partners llc united states t partners llc united states jumpcom inc united states  ontario inc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact eventide asset management llc please visit wwweventidefundscom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft eventide  about us about us eventide asset management llc is a bostonbased registered investment advisor and serves as the advisor to eventide mutual funds founded in  with a vision to provide high performance valuesbased investments for individuals financial advisors and institutions eventide has become a leader in faithbased and socially responsible investing eventide is the advisor to the eventide gilead fund the eventide healthcare  life sciences fund and the eventide multiasset income fund and manages more than  billion in net assets leadership investment team sales and marketing our investment philosophy purpose and values we believe highquality companies where we have a differentiated view from the market and that trade at a discount to intrinsic value offer superior longterm riskadjusted returns the advisers judgment about the quality and intrinsic value of particular companies may prove to be incorrect there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses eventide strives to honor god and serve its clients by investing in companies that create compelling value for the global common good we seek to invest shareholder capital in ways that enable our investors to meet their financial endpoints while enlarging the locus of flourishing in the world we believe value creation is the essential mark of great companies – those companies that are both attractive for investment and truly admirable our goal is to invest in such companies we take a broad stakeholder perspective on value creation – seeking to invest in those companies that excel at serving their customers employees suppliers host communities the environment and society broadly eventidevalues constantly improving eventide people are those with a sense of the ideal in every aspect of their work as a result we take the posture of learners and constantly and indefatigably work to grow in knowledge discernment and competence teachable in an industry often characterized by selfaggrandizement eventide people seek to have an accurate selfassessment to be open to critique and teachable recognizing our perspectives can be incomplete and our weaknesses often transparent we seek to have the humility required to learn from others and thereby truly advance bold eventide people have the boldness to stand apart whether in our resolve to always select for investments that conduce to the human good our focus on longterm success or our willingness to depart from consensus opinion we have the boldness to be singularly different content only with excellence eventide people prefer the artisan to the industrial we pay attention to craft and detail and seek to be rightly proud of everything we do thoughtful eventide people seek to be disciplined and rational we seek to read broadly contemplate from diverse vantage points and to act thoughtfully and for good reason high integrity eventide people seek to be persons of high integrity we want to act virtuously speak candidly and live our authentic selves before others collaborative eventide people believe that together they can achieve more than they can independently therefore we value diversity of thought and seek to foster a working environment that is collaborative and where each contribution is important sales and marketing jason myhre director of marketing  advisory services managing partner jason myhre serves as the director of marketing and advisory services for eventide he is responsible for eventide’s internal support and service to advisory relationships overseeing eventide’s advisory services team including the product specialist team prior to eventide mr myhre worked in internal sales and managed key customer relationships for altec he holds a master’s and bachelor’s degree from the university of florida and studied architecture at harvard’s graduate school of design jeff cave cima® director of distribution jeff cave serves as the director of distribution for eventide he is responsible for external sales and distribution prior to joining eventide in  mr cave was with merrill lynch for almost  years most recently as director ultra high net worth wealth management specialist for the private banking and investment group at merrill lynch based in new york city mr cave holds the certified investment management analyst certification administered by investment management consultants association and taught in conjunction with the wharton school at the university of pennsylvania he is a certified kingdom advisor and member of the board of kingdom advisors and the board of managers for the ron blue institute for financial planning he holds an mba from the university of minnesota and a bba in management and marketing from loyola university harry nelson cima® director of institutional markets harry nelson serves as the director of institutional markets for eventide he is responsible for institutional sales and key account relationships prior to joining eventide in  harry was president of guidestone capital management llc before that mr nelson served in business development roles at guidestone and golden capital management harry holds the certified investment management analyst certification administered by investment management consultants association and taught in conjunction with the wharton school of business at the university of pennsylvania he earned his ba in political science from the citadel rob moll director of communications  advocacy rob moll serves as eventide’s director of communications and advocacy helping to shape and share eventides mission of valuesbased investing prior to joining eventide rob was communications officer to the president at world vision a global christian humanitarian organization rob is editor at large for christianity today magazine and the author of two books his writing has appeared in the wall street journal the washington post time forbescom and numerous other publications members of the media can contact rob for interviews and information portfolio managers finny kuruvilla md phd chief investment officer portfolio manager managing partner finny kuruvilla serves as the cio for eventide funds lead portfolio manager on the eventide gilead fund and portfolio manager on the eventide healthcare  life sciences fund dr kuruvilla has a unique background in healthcare statistics and investing concurrent with eventide from  through  he was a principal at clarus ventures a leading healthcare and life sciences venture capital firm prior to joining eventide from  dr kuruvilla was a research fellow at the broad institute of harvard and mit and from  dr kuruvilla was a clinical fellow at the brigham and women’s hospital and children’s hospital boston and a postdoctoral scientist at mit he holds an md from harvard medical school a phd in chemistry and chemical biology from harvard university a master’s degree in electrical engineering and computer science from mit and a bachelor’s degree from caltech in chemistry martin wildy cfa portfolio manager martin wildy cfa serves as portfolio manager of eventide’s multiasset income fund prior to joining eventide in  mr wildy was a senior portfolio manager with aris wealth services a division of assetmark inc where he worked since september  previously mr wildy was an equity analyst at  investment advisors inc where he was responsible for equity research and recommendations primarily within the telecommunication technology and regional banking sectors mr wildy holds a bachelor’s degree from the pennsylvania state university in finance and has held the chartered financial analyst cfa designation since  in addition to his role at eventide mr wildy is an active volunteer and consultant with the cfa institute supporting the cfa examination process as well as the cfa digest publication david barksdale chief financial officer portfolio manager managing partner david barksdale serves as eventide’s cfo and is a coportfolio manager on the eventide gilead fund in addition to managing financial operations for eventide he is responsible for developing and applying novel analytical tools and strategies in support of eventide’s portfolio management prior to joining eventide in  mr barksdale served as a senior services manager with cadence design systems an information technology company he holds a bachelor’s degree from caltech in engineering  applied science research analysts andrew singer cfa senior research analyst andrew singer cfa serves as senior analyst for eventide mr singer is responsible for making investment recommendations and monitoring existing portfolio investments by conducting fundamental financial and valuation analyses prior to joining eventide mr singer held investment analyst positions at credit suisse blackrock and john hancock where he focused on small and midcap equities across a variety of sectors he has a bachelor’s degree in quantitative economics from tufts university and an mba from babson college mr singer holds the chartered financial analyst designation and is a member of the boston security analysts society and cfa institute agustin mohedas phd research analyst agustin mohedas serves as a research analyst for eventide he is primarily responsible for evaluating and monitoring new and existing healthcare investment opportunities in the portfolios prior to joining eventide dr mohedas was an investment analyst at ra capital where he focused on evidencebased investing in small and midcap life science equities dr mohedas holds a bs in biomedical engineering from texas am university and a phd in medical engineering medical physics from the harvardmit division of health sciences and technology in his doctoral research agustin developed small molecule compounds to treat fibrodysplasia ossificans progressiva a rare and devastating genetic disorder anant goel research analyst anant goel serves as a research analyst for eventide he is primarily responsible for evaluating and monitoring new and existing investment opportunities in the portfolios mr goel has an mba from the mit sloan school of management during which time he worked at adage capital management prior to mit he was an analyst for newquest capital partners the leading secondary private equity platform in asia he holds a bsc hons from the university of warwick uk in economics and is a cfa level iii candidate tianxiang chen computational equity analyst tianxiang chen serves as computational equity analyst for eventides portfolio management team in his role mr chen provides quantitative portfolio analysis investment strategies implementation and top down equity research mr chen has a masters degree in mathematical finance from boston university during which time he worked at acadian asset management he holds a dual bachelors degree in statistical mathematics and computer science with an economics minor from university of virginia portfolio operations colin delaney director of portfolio operations product specialist colin delaney serves as director of portfolio operations and is a product specialist for the advisory services team at eventide in his role in portfolio operations mr delaney works closely with the funds portfolio managers and the investment team to help implement their investment strategies in his role as product specialist mr delaney acts as a link between eventides investment team and our client advisors helping them understand the portfolios investments and strategies prior to eventide mr delaney was a senior vice president at jefferies llc where he served as a sales trader and client relations manager in nearly  years at jefferies he was able to participate in a broad range of investment activities giving him a deep and wide understanding of the complete investment process mr delaney has a degree in economics from st lawrence university executive team robin john chief executive officer managing partner robin john is cofounder and chief executive officer of eventide he is responsible for the overall leadership of the organization and under his leadership the firm has grown into a leader within values based investing prior to eventide mr john held leadership roles for bank of new york mellon he has also served as a business consultant for grant thornton he has a degree in economics from tufts university connect with robin on linkedin finny kuruvilla md phd chief investment officer portfolio manager managing partner finny kuruvilla serves as the cio for eventide funds lead portfolio manager on the eventide gilead fund and portfolio manager on the eventide healthcare  life sciences fund dr kuruvilla has a unique background in healthcare statistics and investing concurrent with eventide from  through  he was a principal at clarus ventures a leading healthcare and life sciences venture capital firm prior to joining eventide from  dr kuruvilla was a research fellow at the broad institute of harvard and mit and from  dr kuruvilla was a clinical fellow at the brigham and women’s hospital and children’s hospital boston and a postdoctoral scientist at mit he holds an md from harvard medical school a phd in chemistry and chemical biology from harvard university a master’s degree in electrical engineering and computer science from mit and a bachelor’s degree from caltech in chemistry david barksdale chief financial officer portfolio manager managing partner david barksdale serves as eventide’s cfo and is a coportfolio manager on the eventide gilead fund in addition to managing financial operations for eventide he is responsible for developing and applying novel analytical tools and strategies in support of eventide’s portfolio management prior to joining eventide in  mr barksdale served as a senior services manager with cadence design systems an information technology company he holds a bachelor’s degree from caltech in engineering  applied science jason myhre director of marketing  advisory services managing partner jason myhre serves as the director of marketing and advisory services for eventide he is responsible for eventide’s internal support and service to advisory relationships overseeing eventide’s advisory services team including the product specialist team prior to eventide mr myhre worked in internal sales and managed key customer relationships for altec he holds a master’s and bachelor’s degree from the university of florida and studied architecture at harvard’s graduate school of design peter luiso chief compliance officer and general counsel peter luiso serves eventide as cco managing eventide’s compliance program prior to joining eventide in june  peter held several roles at fidelity investments most recently deputy cco of fidelity’s strategic advisers funds where he provided regulatory guidance to many of fidelity’s investment advisers brokerdealers and retirement businesses before that mr luiso served as a senior enforcement attorney for the us securities and exchange commission and as trial counsel for the new york stock exchange peter holds a bachelor’s degree in criminal justice from northeastern university in boston and a jd from georgia state university college of law in atlanta bj cheriakalath director of compliance bj cheriakalath serves as director of compliance at eventide he works to ensure compliance with applicable regulatory and procedural requirements including the funds’ adherence to prospectussai restrictions prior to joining eventide mr cheriakalath served as a supervisor at bank of new york mellon’s corporate actions department he has a degree in economics from tufts university  registration of an investment adviser does not imply certain level of skill or training nor does it imply endorsement by the sec  there is no guarantee that the advisor will meet its objectives mutual funds involve risk including the possible loss of principal past performance does not guarantee future resultsthe funds’ ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria the funds can have risk related to option investing there are special risks associated with investments in foreign companies including exposure to currency fluctuations less efficient trading markets political instability and differing auditing and legal standards because of ongoing market volatility the funds performance may be subject to substantial shortterm changes the eventide gilead fund  eventide healthcare  life sciences fund can invest in smallersized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies the funds can also have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the us food and drug administration the funds can invest in private companies private investments include various risks including but not limited to lack of liquidity capital commitment risk and valuation risk private companies may not be financially profitable and have uncertain futures subjecting them to additional risks investors in the gilead fund should be aware that companies in the technology industries have different risks including but not limited to products becoming obsolete and entrance of competing products companies in the industrial sector also carry various risks including but not limited to risk related to debt loads and intense competition investors in the eventide multiasset income fund should be aware that interest rates are at historic lows and may change at any time based on government policy in general the price of a fixed income security falls when interest rates rise a rise in interest rates may result in volatility and increased redemptions which in turn could result in the fund being forced to liquidate portfolio securities at disadvantageous prices longerterm securities may be more sensitive to changes in interest rates the intermediateterm bond portion of the fund’s portfolio may represent  to  of the fund’s portfolio with an average duration of between two and eight years the eventide multiasset income fund may invest in other funds if other funds are utilized such underlying funds are subject to investment advisory and other expenses which will be indirectly paid by the fund as a result your cost of investing in the fund will be higher than the cost of investing directly in underlying funds and may be higher than other mutual funds that do not invest in underlying funds the fund may invest directly or indirectly in “junk bonds” such securities are speculative investments that carry greater risks than higher quality debt securities there are unique risks associated with reits mlps preferred stocks convertible bonds bdcs and yieldcos that are covered in the funds prospectus and sai the fund is a new mutual fund and has a limited history of operations for investors to evaluate an investor should consider a funds investment objectives risks charges and expenses carefully before investing or sending money this and other important information can be found in the prospectus which can be obtained at wwweventidefundscom or by calling even  please read the prospectus carefully before investing eventide mutual funds are distributed by northern lights distributors llc member finra which is not affiliated with eventide asset management llc eventide  about us about us eventide asset management llc is a bostonbased registered investment advisor and serves as the advisor to eventide mutual funds founded in  with a vision to provide high performance valuesbased investments for individuals financial advisors and institutions eventide has become a leader in faithbased and socially responsible investing eventide is the advisor to the eventide gilead fund the eventide healthcare  life sciences fund and the eventide multiasset income fund and manages more than  billion in net assets leadership investment team sales and marketing our investment philosophy purpose and values we believe highquality companies where we have a differentiated view from the market and that trade at a discount to intrinsic value offer superior longterm riskadjusted returns the advisers judgment about the quality and intrinsic value of particular companies may prove to be incorrect there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses eventide strives to honor god and serve its clients by investing in companies that create compelling value for the global common good we seek to invest shareholder capital in ways that enable our investors to meet their financial endpoints while enlarging the locus of flourishing in the world we believe value creation is the essential mark of great companies – those companies that are both attractive for investment and truly admirable our goal is to invest in such companies we take a broad stakeholder perspective on value creation – seeking to invest in those companies that excel at serving their customers employees suppliers host communities the environment and society broadly eventidevalues constantly improving eventide people are those with a sense of the ideal in every aspect of their work as a result we take the posture of learners and constantly and indefatigably work to grow in knowledge discernment and competence teachable in an industry often characterized by selfaggrandizement eventide people seek to have an accurate selfassessment to be open to critique and teachable recognizing our perspectives can be incomplete and our weaknesses often transparent we seek to have the humility required to learn from others and thereby truly advance bold eventide people have the boldness to stand apart whether in our resolve to always select for investments that conduce to the human good our focus on longterm success or our willingness to depart from consensus opinion we have the boldness to be singularly different content only with excellence eventide people prefer the artisan to the industrial we pay attention to craft and detail and seek to be rightly proud of everything we do thoughtful eventide people seek to be disciplined and rational we seek to read broadly contemplate from diverse vantage points and to act thoughtfully and for good reason high integrity eventide people seek to be persons of high integrity we want to act virtuously speak candidly and live our authentic selves before others collaborative eventide people believe that together they can achieve more than they can independently therefore we value diversity of thought and seek to foster a working environment that is collaborative and where each contribution is important sales and marketing jason myhre director of marketing  advisory services managing partner jason myhre serves as the director of marketing and advisory services for eventide he is responsible for eventide’s internal support and service to advisory relationships overseeing eventide’s advisory services team including the product specialist team prior to eventide mr myhre worked in internal sales and managed key customer relationships for altec he holds a master’s and bachelor’s degree from the university of florida and studied architecture at harvard’s graduate school of design jeff cave cima® director of distribution jeff cave serves as the director of distribution for eventide he is responsible for external sales and distribution prior to joining eventide in  mr cave was with merrill lynch for almost  years most recently as director ultra high net worth wealth management specialist for the private banking and investment group at merrill lynch based in new york city mr cave holds the certified investment management analyst certification administered by investment management consultants association and taught in conjunction with the wharton school at the university of pennsylvania he is a certified kingdom advisor and member of the board of kingdom advisors and the board of managers for the ron blue institute for financial planning he holds an mba from the university of minnesota and a bba in management and marketing from loyola university harry nelson cima® director of institutional markets harry nelson serves as the director of institutional markets for eventide he is responsible for institutional sales and key account relationships prior to joining eventide in  harry was president of guidestone capital management llc before that mr nelson served in business development roles at guidestone and golden capital management harry holds the certified investment management analyst certification administered by investment management consultants association and taught in conjunction with the wharton school of business at the university of pennsylvania he earned his ba in political science from the citadel rob moll director of communications  advocacy rob moll serves as eventide’s director of communications and advocacy helping to shape and share eventides mission of valuesbased investing prior to joining eventide rob was communications officer to the president at world vision a global christian humanitarian organization rob is editor at large for christianity today magazine and the author of two books his writing has appeared in the wall street journal the washington post time forbescom and numerous other publications members of the media can contact rob for interviews and information portfolio managers finny kuruvilla md phd chief investment officer portfolio manager managing partner finny kuruvilla serves as the cio for eventide funds lead portfolio manager on the eventide gilead fund and portfolio manager on the eventide healthcare  life sciences fund dr kuruvilla has a unique background in healthcare statistics and investing concurrent with eventide from  through  he was a principal at clarus ventures a leading healthcare and life sciences venture capital firm prior to joining eventide from  dr kuruvilla was a research fellow at the broad institute of harvard and mit and from  dr kuruvilla was a clinical fellow at the brigham and women’s hospital and children’s hospital boston and a postdoctoral scientist at mit he holds an md from harvard medical school a phd in chemistry and chemical biology from harvard university a master’s degree in electrical engineering and computer science from mit and a bachelor’s degree from caltech in chemistry martin wildy cfa portfolio manager martin wildy cfa serves as portfolio manager of eventide’s multiasset income fund prior to joining eventide in  mr wildy was a senior portfolio manager with aris wealth services a division of assetmark inc where he worked since september  previously mr wildy was an equity analyst at  investment advisors inc where he was responsible for equity research and recommendations primarily within the telecommunication technology and regional banking sectors mr wildy holds a bachelor’s degree from the pennsylvania state university in finance and has held the chartered financial analyst cfa designation since  in addition to his role at eventide mr wildy is an active volunteer and consultant with the cfa institute supporting the cfa examination process as well as the cfa digest publication david barksdale chief financial officer portfolio manager managing partner david barksdale serves as eventide’s cfo and is a coportfolio manager on the eventide gilead fund in addition to managing financial operations for eventide he is responsible for developing and applying novel analytical tools and strategies in support of eventide’s portfolio management prior to joining eventide in  mr barksdale served as a senior services manager with cadence design systems an information technology company he holds a bachelor’s degree from caltech in engineering  applied science research analysts andrew singer cfa senior research analyst andrew singer cfa serves as senior analyst for eventide mr singer is responsible for making investment recommendations and monitoring existing portfolio investments by conducting fundamental financial and valuation analyses prior to joining eventide mr singer held investment analyst positions at credit suisse blackrock and john hancock where he focused on small and midcap equities across a variety of sectors he has a bachelor’s degree in quantitative economics from tufts university and an mba from babson college mr singer holds the chartered financial analyst designation and is a member of the boston security analysts society and cfa institute agustin mohedas phd research analyst agustin mohedas serves as a research analyst for eventide he is primarily responsible for evaluating and monitoring new and existing healthcare investment opportunities in the portfolios prior to joining eventide dr mohedas was an investment analyst at ra capital where he focused on evidencebased investing in small and midcap life science equities dr mohedas holds a bs in biomedical engineering from texas am university and a phd in medical engineering medical physics from the harvardmit division of health sciences and technology in his doctoral research agustin developed small molecule compounds to treat fibrodysplasia ossificans progressiva a rare and devastating genetic disorder anant goel research analyst anant goel serves as a research analyst for eventide he is primarily responsible for evaluating and monitoring new and existing investment opportunities in the portfolios mr goel has an mba from the mit sloan school of management during which time he worked at adage capital management prior to mit he was an analyst for newquest capital partners the leading secondary private equity platform in asia he holds a bsc hons from the university of warwick uk in economics and is a cfa level iii candidate tianxiang chen computational equity analyst tianxiang chen serves as computational equity analyst for eventides portfolio management team in his role mr chen provides quantitative portfolio analysis investment strategies implementation and top down equity research mr chen has a masters degree in mathematical finance from boston university during which time he worked at acadian asset management he holds a dual bachelors degree in statistical mathematics and computer science with an economics minor from university of virginia portfolio operations colin delaney director of portfolio operations product specialist colin delaney serves as director of portfolio operations and is a product specialist for the advisory services team at eventide in his role in portfolio operations mr delaney works closely with the funds portfolio managers and the investment team to help implement their investment strategies in his role as product specialist mr delaney acts as a link between eventides investment team and our client advisors helping them understand the portfolios investments and strategies prior to eventide mr delaney was a senior vice president at jefferies llc where he served as a sales trader and client relations manager in nearly  years at jefferies he was able to participate in a broad range of investment activities giving him a deep and wide understanding of the complete investment process mr delaney has a degree in economics from st lawrence university executive team robin john chief executive officer managing partner robin john is cofounder and chief executive officer of eventide he is responsible for the overall leadership of the organization and under his leadership the firm has grown into a leader within values based investing prior to eventide mr john held leadership roles for bank of new york mellon he has also served as a business consultant for grant thornton he has a degree in economics from tufts university connect with robin on linkedin finny kuruvilla md phd chief investment officer portfolio manager managing partner finny kuruvilla serves as the cio for eventide funds lead portfolio manager on the eventide gilead fund and portfolio manager on the eventide healthcare  life sciences fund dr kuruvilla has a unique background in healthcare statistics and investing concurrent with eventide from  through  he was a principal at clarus ventures a leading healthcare and life sciences venture capital firm prior to joining eventide from  dr kuruvilla was a research fellow at the broad institute of harvard and mit and from  dr kuruvilla was a clinical fellow at the brigham and women’s hospital and children’s hospital boston and a postdoctoral scientist at mit he holds an md from harvard medical school a phd in chemistry and chemical biology from harvard university a master’s degree in electrical engineering and computer science from mit and a bachelor’s degree from caltech in chemistry david barksdale chief financial officer portfolio manager managing partner david barksdale serves as eventide’s cfo and is a coportfolio manager on the eventide gilead fund in addition to managing financial operations for eventide he is responsible for developing and applying novel analytical tools and strategies in support of eventide’s portfolio management prior to joining eventide in  mr barksdale served as a senior services manager with cadence design systems an information technology company he holds a bachelor’s degree from caltech in engineering  applied science jason myhre director of marketing  advisory services managing partner jason myhre serves as the director of marketing and advisory services for eventide he is responsible for eventide’s internal support and service to advisory relationships overseeing eventide’s advisory services team including the product specialist team prior to eventide mr myhre worked in internal sales and managed key customer relationships for altec he holds a master’s and bachelor’s degree from the university of florida and studied architecture at harvard’s graduate school of design peter luiso chief compliance officer and general counsel peter luiso serves eventide as cco managing eventide’s compliance program prior to joining eventide in june  peter held several roles at fidelity investments most recently deputy cco of fidelity’s strategic advisers funds where he provided regulatory guidance to many of fidelity’s investment advisers brokerdealers and retirement businesses before that mr luiso served as a senior enforcement attorney for the us securities and exchange commission and as trial counsel for the new york stock exchange peter holds a bachelor’s degree in criminal justice from northeastern university in boston and a jd from georgia state university college of law in atlanta bj cheriakalath director of compliance bj cheriakalath serves as director of compliance at eventide he works to ensure compliance with applicable regulatory and procedural requirements including the funds’ adherence to prospectussai restrictions prior to joining eventide mr cheriakalath served as a supervisor at bank of new york mellon’s corporate actions department he has a degree in economics from tufts university  registration of an investment adviser does not imply certain level of skill or training nor does it imply endorsement by the sec  there is no guarantee that the advisor will meet its objectives mutual funds involve risk including the possible loss of principal past performance does not guarantee future resultsthe funds’ ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria the funds can have risk related to option investing there are special risks associated with investments in foreign companies including exposure to currency fluctuations less efficient trading markets political instability and differing auditing and legal standards because of ongoing market volatility the funds performance may be subject to substantial shortterm changes the eventide gilead fund  eventide healthcare  life sciences fund can invest in smallersized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies the funds can also have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the us food and drug administration the funds can invest in private companies private investments include various risks including but not limited to lack of liquidity capital commitment risk and valuation risk private companies may not be financially profitable and have uncertain futures subjecting them to additional risks investors in the gilead fund should be aware that companies in the technology industries have different risks including but not limited to products becoming obsolete and entrance of competing products companies in the industrial sector also carry various risks including but not limited to risk related to debt loads and intense competition investors in the eventide multiasset income fund should be aware that interest rates are at historic lows and may change at any time based on government policy in general the price of a fixed income security falls when interest rates rise a rise in interest rates may result in volatility and increased redemptions which in turn could result in the fund being forced to liquidate portfolio securities at disadvantageous prices longerterm securities may be more sensitive to changes in interest rates the intermediateterm bond portion of the fund’s portfolio may represent  to  of the fund’s portfolio with an average duration of between two and eight years the eventide multiasset income fund may invest in other funds if other funds are utilized such underlying funds are subject to investment advisory and other expenses which will be indirectly paid by the fund as a result your cost of investing in the fund will be higher than the cost of investing directly in underlying funds and may be higher than other mutual funds that do not invest in underlying funds the fund may invest directly or indirectly in “junk bonds” such securities are speculative investments that carry greater risks than higher quality debt securities there are unique risks associated with reits mlps preferred stocks convertible bonds bdcs and yieldcos that are covered in the funds prospectus and sai the fund is a new mutual fund and has a limited history of operations for investors to evaluate an investor should consider a funds investment objectives risks charges and expenses carefully before investing or sending money this and other important information can be found in the prospectus which can be obtained at wwweventidefundscom or by calling even  please read the prospectus carefully before investing eventide mutual funds are distributed by northern lights distributors llc member finra which is not affiliated with eventide asset management llc eventide  forms  literature forms  literature for information on eventide mutual funds click the appropriate icons below to view and download fund documents such as a prospectus statement of additional information annual report fact sheet or for application forms you can also visit our products page to receive details of the funds’ performance if you would like physical copies of any document please call us at even  or email us at  quarterly fact sheet quarterly commentary summary prospectus summary prospectus sticker prospectus prospectus sticker annual report semiannual report statement of additional information sai yearend distributions account application forms eventide gilead fund application eventide healthcare  life sciences fund application eventide multiasset income fund application eventide gilead fund eventide healthcare  life sciences fund eventide multiasset income fund quarterly fact sheet quarterly commentary summary prospectus summary prospectus sticker prospectus prospectus sticker annual report semiannual report statement of additional information sai yearend distributions account application forms application application application mutual funds involve risk including the possible loss of principal past performance does not guarantee future resultsthe funds’ ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria the funds can have risk related to option investing there are special risks associated with investments in foreign companies including exposure to currency fluctuations less efficient trading markets political instability and differing auditing and legal standards because of ongoing market volatility the funds performance may be subject to substantial shortterm changes the eventide gilead fund  eventide healthcare  life sciences fund can invest in smallersized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies the funds can also have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the us food and drug administration the funds can invest in private companies private investments include various risks including but not limited to lack of liquidity capital commitment risk and valuation risk private companies may not be financially profitable and have uncertain futures subjecting them to additional risks investors in the gilead fund should be aware that companies in the technology industries have different risks including but not limited to products becoming obsolete and entrance of competing products companies in the industrial sector also carry various risks including but not limited to risk related to debt loads and intense competition investors in the eventide multiasset income fund should be aware that interest rates are at historic lows and may change at any time based on government policy in general the price of a fixed income security falls when interest rates rise a rise in interest rates may result in volatility and increased redemptions which in turn could result in the fund being forced to liquidate portfolio securities at disadvantageous prices longerterm securities may be more sensitive to changes in interest rates the intermediateterm bond portion of the fund’s portfolio may represent  to  of the fund’s portfolio with an average duration of between two and eight years the eventide multiasset income fund may invest in other funds if other funds are utilized such underlying funds are subject to investment advisory and other expenses which will be indirectly paid by the fund as a result your cost of investing in the fund will be higher than the cost of investing directly in underlying funds and may be higher than other mutual funds that do not invest in underlying funds the fund may invest directly or indirectly in “junk bonds” such securities are speculative investments that carry greater risks than higher quality debt securities there are unique risks associated with reits mlps preferred stocks convertible bonds bdcs and yieldcos that are covered in the funds prospectus and sai the fund is a new mutual fund and has a limited history of operations for investors to evaluate an investor should consider a funds investment objectives risks charges and expenses carefully before investing or sending money this and other important information can be found in the prospectus which can be obtained at wwweventidefundscom or by calling even  please read the prospectus carefully before investing eventide mutual funds are distributed by northern lights distributors llc member finra which is not affiliated with eventide asset management llc nld eventide  our products our products the goal of eventide mutual funds is to maintain market outperformance by investing in companies that we believe excel at creating value operate with integrity and profit from ethical and sustainable activities we invite individuals advisors and institutions to learn more about our products below including performance holdings prospectus and other details eventide gilead fund eventide healthcare  life sciences fund eventide multiasset income fund overview management portfolio composition performance market risk top holdings literature prospectus and sai objective seeks to provide longterm capital appreciation about the fund a diversified equity mutual fund representing our “best ideas” that seeks to provide longterm capital appreciation historical emphases in small and midcap growth health care and information technology investment process there is no guarantee that the adviser’s investment process will produce the desired results all investments involve risks including possible loss of capital dr finny kuruvilla has a unique background in healthcare statistics and investing he holds an md from harvard medical school a phd in chemistry and chemical biology from harvard university a master’s degree in electrical engineering and computer science from mit and a bachelor’s degree from caltech in chemistry he completed his residency and fellowship at the brigham  women’s hospital and children’s hospital boston where he cared for adult and pediatric patients suffering from a variety of hematologic oncologic and autoimmune disorders subsequently he was a research fellow at mit where he designed and implemented statistical algorithms involving logistic regression and pseudobayesian expectation maximization as an avid proponent of valuesbased investing dr kuruvilla has developed standards for selecting ethical companies at the outset of the stock selection process david barksdale has a background in software development engineering and management and is primarily responsible for quantitative research risk analysis and asset allocation he holds a bachelor’s degree from caltech in engineering  applied science by developing and applying novel analytical tools and strategies mr barksdale works to optimize portfolio returns on a riskadjusted basis there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results as of june    companies valued at greater than  billion are large cap those at less than  billion are small cap portfolio composition is subject to change at any time and should not be considered investment advice  the fund may not invest  or more of its total assets in a particular industry or group of industries a sector is normally composed of many industry groups sector allocation is subject to change at any time and should not be considered investment advice as of june   performance is historic and does not guarantee future results investment return and principal value will fluctuate with changing market conditions so that when redeemed shares may be worth more or less than their original cost current performance may be lower or higher than the data quoted investors cannot directly invest in an index and unmanaged index returns do not reflect any fees expenses or sales charges to obtain the most recent monthend performance information and a current eventide gilead fund prospectus please call the fund toll free at even  eventide gilead fund’s class n expenses total expenses   these charts compare the eventide gilead fund class n’s performance to index performance over the periods shown performance will differ for other fund classes based upon fees and commissions the growth of  chart assumes class n’s inception date of  july  for the indices  the returns shown do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption of fund shares because of ongoing market volatility fund performance may be subject to substantial shortterm changes  the sp  is an index created by standard  poor’s of american stocks with the largest market capitalization it is not an investment product available for purchase the russell midcap growth index measures the performance of the us equity midcap growth segment it includes midcap companies with higher pricetobook ratios and forecasted growth the volatility of the indices may be materially different than that of the fund and investors should not expect the fund to achieve the same results as the indices listed  performance figures for periods greater than  year are annualized the fund’s share classes have different inception dates class n has an inception date of  july  class a and class c have an inception date of  october  class i has an inception date of  february  the indices assume an inception date of  july  as of june    source  morningstar inc  all rights reserved the information contained herein  is proprietary to morningstar andor its content providers  may not be copied or distributed and  is not warranted to be accurate complete or timely neither morningstar nor its content providers are responsible for any damages or losses arising from any use of this information previously this summary sheet sourced market risk data from zephyr styleadvisor including a year measurement period other updates to this summary sheet include information intended to help investors assess performance and risk factors across nearterm and longerterm periods ie trailing years and since inception and risk data associated with the fund’s benchmarks the performance and risk factor comparisons are against the sp  total return index “index” alpha is a measure of performance on a riskadjusted basis it takes the volatility price risk of a fund and compares its riskadjusted performance to the index any excess return of the fund relative to the return of the index is a fund’s alpha beta is a measure of the volatility of a fund relative to the index a beta greater than  is more volatile than the index rsquared measures how a fund’s performance correlates with the index’s performance and it can help assess how likely it is that beta is statistically significant standard deviation of return measures the amount of variation in historical performance from period to period  annualized since inception market risk details assume inception date of  august  and not class n’s actual inception date of  july  as only full month data is included in the market risk calculations there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results as of june   xpo logistics inc  global provider of transportation and logistics solutions macquarie infrastructure corp  aircraft services liquid storage and marine terminals bluebird bio inc  gene therapy and cancer immunotherapy for hematology and oncology lowe’s cos inc   home improvement stores in the us canada and mexico wayfair inc  online sales of furniture and home decor sunopta inc  a leading global organic food company steel dynamics inc  diversified carbonsteel producer and metals recycler wabco holdings inc  improving commercial vehicle safety efficiency and connectivity lam research corp  supplying wafer fabrication equipment for the semiconductor industry abbvie inc  innovationdriven global biopharmaceuticals based on percentage of net assets holdings can change at any time and should not be considered investment advice there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results view the fact sheet commentary and presentation for the eventide gilead fund there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results view prospectus and summary prospectus for the eventide gilead fund view the statement of additional information for the eventide gilead fund download xbrl interactive data for the eventide gilead fund there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results overview management portfolio composition performance market risk top holdings literature prospectus and sai equity mutual fund investing in healthcare and life sciences uses bottomup fundamental research to find companies with the potential to appreciate in value as positive data is released regarding clinical trials and fda feedback and market acceptance of products under normal market conditions the fund will invest at least  percent of its net assets in equity and equityrelated securities of companies in the healthcare and life sciences sectors healthcare and life sciences companies include those companies that derive or are expected to derive  or more of their revenue from healthcare and life science products and services including but not limited to biotechnology pharmaceuticals diagnostics life science tools medical devices healthcare information technology healthcare services synthetic biology agricultural and environmental management and pharmaceutical manufacturing products and services these companies include smaller developmentstage companies there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results dr finny kuruvilla has a unique background in healthcare statistics and investing he holds an md from harvard medical school a phd in chemistry and chemical biology from harvard university a master’s degree in electrical engineering and computer science from mit and a bachelor’s degree from caltech in chemistry he completed his residency and fellowship at the brigham  women’s hospital and children’s hospital boston where he cared for adult and pediatric patients suffering from a variety of hematologic oncologic and autoimmune disorders subsequently he was a research fellow at mit where he designed and implemented statistical algorithms involving logistic regression and pseudobayesian expectation maximization as an avid proponent of valuesbased investing dr kuruvilla has developed standards for selecting ethical companies at the outset of the stock selection process there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results as of june    companies valued at greater than  billion are large cap those at less than  billion are small cap portfolio composition is subject to change at any time and should not be considered investment advice  industry allocation is subject to change at any time and should not be considered investment advice there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results as of june   performance is historic and does not guarantee future results investment return and principal value will fluctuate with changing market conditions so that when redeemed shares may be worth more or less than their original cost current performance may be lower or higher than the data quoted investors cannot directly invest in an index and unmanaged index returns do not reflect any fees expenses or sales charges to obtain the most recent monthend performance information and a current eventide healthcare  life sciences fund prospectus please call the fund toll free at even  eventide healthcare  life sciences fund’s class n expenses net expenses   these charts compare the eventide healthcare  life sciences fund class n’s performance to index performance over the periods shown performance will differ for other fund classes based upon fees and commissions the growth of  chart assumes the fund’s inception date of  december  for the indices  the returns shown do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption of fund shares because of ongoing market volatility fund performance may be subject to substantial shortterm changes  the sp  is an index created by standard  poor’s of american stocks with the largest market capitalization it is not an investment product available for purchase the healthcare blended index is composed of equal parts of the sp  healthcare index and the sp  healthcare index from fund inception on  december  the sp biotechnology select industry index represents the biotechnology subindustry portion of the sp total markets index the secondary index for the fund changed from the healthcare blended index to the sp biotechnology select industry index on april   this change was made because the adviser believes that the composition of the sp biotechnology select industry index better reflects the risks and opportunities of the fund’s portfolio the performance of both indices will be shown for a period of one year thereafter the performance of the healthcare blended index will no longer be shown on the summary sheet the volatility of the indices may be materially different than that of the fund and investors should not expect the fund to achieve the same results as the indices listed  performance figures for periods greater than  year are annualized annualized since inception returns assume an inception date of  december  performance is historical and does not guarantee future results investment return and principal value will fluctuate with changing market conditions so that when redeemed shares may be worth more or less than their original cost current performance may be lower or higher than the data quoted investors cannot directly invest in an index and unmanaged index returns do not reflect any fees expenses or sales charges to obtain the most recent monthend performance information and a current eventide healthcare  life sciences fund prospectus please call the fund toll free at even  there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results as of june    source  morningstar inc  all rights reserved the information contained herein  is proprietary to morningstar andor its content providers  may not be copied or distributed and  is not warranted to be accurate complete or timely neither morningstar nor its content providers are responsible for any damages or losses arising from any use of this information previously this summary sheet sourced market risk data from zephyr styleadvisor other updates to this summary sheet include information intended to help investors assess performance and risk factors associated with the fund’s benchmarks the performance and risk factor comparisons are against the sp  total return index “index” alpha is a measure of performance on a riskadjusted basis it takes the volatility price risk of a fund and compares its riskadjusted performance to the index any excess return of the fund relative to the return of the index is a fund’s alpha beta is a measure of the volatility of a fund relative to the index a beta greater than  is more volatile than the index rsquared measures how a fund’s performance correlates with the index’s performance and it can help assess how likely it is that beta is statistically significant standard deviation of return measures the amount of variation in historical performance from period to period  annualized since inception market risk details assume inception date of  january  and not fund’s actual inception date of  december  as only full month data is included in the market risk calculations there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results as of june   loxo oncology inc  treating cancer at the genomic level with targeted chemical therapies blueprint medicines corp  next generation kinase therapies for genomically defined diseases bluebird bio inc  gene therapy and cancer immunotherapy for hematology and oncology collegium pharmaceutical inc  abusedeterrant treatments for chronic pain celgene corp  discovery development and commercialization of lifechanging cancer therapies spark therapeutics inc  innovating gene therapies for inherited diseases kite pharma inc  leader in immunooncology using engineered t cell therapy ascendis pharma as  rare diseasesfocused biopharmaceutical company abbvie inc  innovationdriven global biopharmaceuticals avexis inc  clinical stage gene therapy for lifethreatening diseases based on percentage of net assets holdings can change at any time and should not be considered investment advice there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results view the fact sheet commentary and presentation for the eventide healthcare  life sciences fund there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results view prospectus and summary prospectus for the eventide healthcare  life sciences fund view the statement of additional information for the eventide healthcare  life sciences fund download xbrl interactive data for the eventide healthcare  life sciences fund there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results overview management portfolio composition performance market risk top holdings literature prospectus and sai investment objective the eventide multiasset income fund seeks current income while maintaining the potential for capital appreciation the fund has significant flexibility to achieve its investment objective by primarily investing in a broad universe of incomeproducing securities these securities include debt and equity securities of companies in the us and other markets around the world these securities may include but are not limited to common stocks real estate investment trusts reits business development companies yieldcos master limited partnerships mlps preferred stocks corporate bonds government agency bonds certificates of deposit municipal bonds inflationlinked bonds mortgagebacked securities options exchange traded notes exchange traded funds and other investment companies including mutual funds and closedend funds the fund may invest up to  of its net assets in companies whose securities may have legal or contractual restrictions on resale or are otherwise illiquid investment strategy eventide uses a two step process to select securities for the fund the investment process begins with a “top down” analysis to select a variety of asset classes that are believed to offer the best opportunity for current income andor capital appreciation factors considered include an assessment of current income opportunities the potential for income growth valuation capital appreciation potential andor portfolio riskreturn attributes the second step is a fundamental “bottomup” analysis to evaluate specific securities for inclusion in the portfolio eventide favors securities that in its opinion are attractively valued provide attractive current income provide income appreciation potential provide capital appreciation potential andor help to reduce overall portfolio volatility subadviser eventide has retained boyd watterson asset management llc to manage some or all of the fund’s assets allocated for investment in the intermediateterm bond portion of the portfolio in selecting securities for investment by the fund boyd watterson employs a topdown approach to determine how to structure the bond allocation taking in to consideration duration maturity and sector allocation boyd watterson then initiates a process of security analysis based on several factors including but not limited to economic trends industry assessments and issuer specific credit fundamentals valuesbased investing eventide aims to analyze each potential investment’s ability to operate with integrity and create value for customers employees the environment and other key stakeholders while few companies may reach these ideals in every area of their business these principles articulate the advisor’s ideal characteristics of good corporate behavior the advisor makes no guarantee that fund investments will meet any or all of these characteristics learn more about the eventide multiasset income fund in this presentation there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results martin wildy cfa serves in eventide’s portfolio management team as the lead portfolio manager for the eventide multiasset income fund prior to joining eventide in  mr wildy was a senior portfolio manager with aris wealth services a division of assetmark inc where he worked since  mr wildy served on aris’s investment committee and was responsible for investment decisions that impacted a number of the firm’s investment strategies including aris’ income builder and valuesbased portfolios in his role mr wildy’s responsibilities included developing capital market assumptions asset allocation decisions investment due diligence and portfolio management mr wildy holds a bachelor’s degree from the pennsylvania state university in finance and has held the chartered financial analyst cfa designation since  david m dirk cfa serves as the portfolio manager for some or all of the fund’s intermediateterm bond portion mr dirk has been codirector of fixed income for the fund’s subadvisor boyd watterson with responsibility of directing all portfolio management and trading activity since  this includes the implementation execution and evaluation of all strategies across boyd watterson’s suite of fixed income products mr dirk joined duff  phelps predecessor to boyd watterson asset management in  david holds a cfa charter from cfa institute an mba from case western reserve university and a ba from baldwinwallace college he is also a member of the cfa society of cleveland and cfa institute eventide’s portfolio management team offers input dr finny kuruvilla eventide’s chief investment officer serves in an oversight capacity for all of the firm’s investment strategies while david barksdale provides quantitative analysis and tools which assist in the management of the fund there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results as of june    fund allocation percentages are subject to change at any time and should not be considered investment advice included in the cashother sections is a derivatives exposure of   representing short call positions covered calls and short put positions cash secured puts there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results as of june   performance is historic and does not guarantee future results investment return and principal value will fluctuate with changing market conditions so that when redeemed shares may be worth more or less than their original cost current performance may be lower or higher than the data quoted investors cannot directly invest in an index and unmanaged index returns do not reflect any fees expenses or sales charges to obtain the most recent monthend performance information and a current eventide multiasset income fund prospectus please call the fund toll free at even  eventide multiasset income fund class n expenses net expenses   the numbers shown do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption of fund shares because of ongoing market volatility fund performance may be subject to substantial shortterm changes  the chart compares the eventide multiasset income fund class n’s growth to index growth since inception and assumes the fund’s inception date of  july  for the indices growth will differ for other fund classes based upon fees and commissions  the multiasset income blend is a proprietary eventide benchmark based on  msci all country world index net  barcap aggregate bond index at inception rebalanced monthly the msci world allcountry world index net captures large and mid cap representation across  developed markets and  emerging markets the volatility of the indices may be materially different than that of the fund and investors should not expect the fund to achieve the same results as the indices listed  the chart displays the eventide multiasset income fund class n’s dividend and capital gains distributions for the periods shown the distributions will differ for other fund classes based upon fees and commissions the total distribution may represent dividend and interest income capital gains andor return of capital shareholders should not assume that the source of a distribution from the fund is net profit the characterization of income is an estimate only and subject to change for tax purposes  nav presented is as of the date of the respective quarter end  source morningstar inc  performance figures for periods greater than  year are annualized annualized since inception returns assume an inception date of  july  as of june    source  morningstar inc  all rights reserved the information contained herein  is proprietary to morningstar andor its content providers  may not be copied or distributed and  is not warranted to be accurate complete or timely neither morningstar nor its content providers are responsible for any damages or losses arising from any use of this information previously this summary sheet sourced market risk data from zephyr styleadvisor other updates to this summary sheet include information intended to help investors assess performance and risk factors associated with the fund’s benchmarks the performance and risk factor comparisons are against the sp  total return index “index” alpha is a measure of performance on a riskadjusted basis it takes the volatility price risk of a fund and com pares its riskadjusted performance to the index any excess return of the fund relative to the return of the index is a fund’s alpha beta is a measure of the volatility of a fund relative to the index a beta greater than  is more volatile than the index rsquared measures how a fund’s performance correlates with the index’s performance and it can help assess how likely it is that beta is statistically significant standard deviation of return measures the amount of variation in historical performance from period to period  since inception market risk details assume inception date of  august  and not class n’s actual inception date of  july  as only full month data is included in the market risk calculations there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results as of june   nextera energy partners lp  yieldco for clean energy projects with stable longterm cash flows spectra energy partners lp  energy infrastructure for transport and storage of natural gas stone ridge reinsurance risk premium interval  catastrophe bonds and reinsurance macquarie infrastructure corp  aircraft services liquid storage and marine terminals johnson controls international plc  global diversified technology and industrial leader abb ltd  tech leader working with utility industry transportation and infrastructure companies brookfield renewable partners lp  wind and hydropower facilities in europe and the americas hannon armstrong sustainable infrastructure  debt and equity investments atlantia spa  manages global transportation infrastructures schneider electric se  global specialist in energy management and automation does not include money market funds based on percentage of net assets holdings can change at any time and should not be considered investment advice there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results view the fact sheet commentary and presentation for the eventide multiasset income fund there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results view prospectus and summary prospectus for the eventide multiasset income fund view the statement of additional information for the eventide multiasset income fund download xbrl interactive data for the eventide multiasset income fund there is no guarantee that any investment will achieve its objectives generate positive returns or avoid losses past performance is not assurance of future results mutual funds involve risk including the possible loss of principal past performance does not guarantee future resultsthe funds’ ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria the funds can have risk related to option investing there are special risks associated with investments in foreign companies including exposure to currency fluctuations less efficient trading markets political instability and differing auditing and legal standards because of ongoing market volatility the funds performance may be subject to substantial shortterm changes the eventide gilead fund  eventide healthcare  life sciences fund can invest in smallersized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies the funds can also have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the us food and drug administration the funds can invest in private companies private investments include various risks including but not limited to lack of liquidity capital commitment risk and valuation risk private companies may not be financially profitable and have uncertain futures subjecting them to additional risks investors in the gilead fund should be aware that companies in the technology industries have different risks including but not limited to products becoming obsolete and entrance of competing products companies in the industrial sector also carry various risks including but not limited to risk related to debt loads and intense competition investors in the eventide multiasset income fund should be aware that interest rates are at historic lows and may change at any time based on government policy in general the price of a fixed income security falls when interest rates rise a rise in interest rates may result in volatility and increased redemptions which in turn could result in the fund being forced to liquidate portfolio securities at disadvantageous prices longerterm securities may be more sensitive to changes in interest rates the intermediateterm bond portion of the fund’s portfolio may represent  to  of the fund’s portfolio with an average duration of between two and eight years the eventide multiasset income fund may invest in other funds if other funds are utilized such underlying funds are subject to investment advisory and other expenses which will be indirectly paid by the fund as a result your cost of investing in the fund will be higher than the cost of investing directly in underlying funds and may be higher than other mutual funds that do not invest in underlying funds the fund may invest directly or indirectly in “junk bonds” such securities are speculative investments that carry greater risks than higher quality debt securities there are unique risks associated with reits mlps preferred stocks convertible bonds bdcs and yieldcos that are covered in the funds prospectus and sai the fund is a new mutual fund and has a limited history of operations for investors to evaluate an investor should consider a funds investment objectives risks charges and expenses carefully before investing or sending money this and other important information can be found in the prospectus which can be obtained at wwweventidefundscom or by calling even  please read the prospectus carefully before investing eventide mutual funds are distributed by northern lights distributors llc member finra which is not affiliated with eventide asset management llc nld eventide  news news eventide issues press releases to highlight industry awards and performance recognition and to share significant announcements and company milestones eventide mutual funds and our portfolio managers are also periodically mentioned and highlighted in the news you can find the latest press releases and news pertaining to eventide and our mutual funds below press releases eventide healthcare  life sciences fund named wsj category king for health  biotech may   eventide funds announces  results february   eventide asset management hires chief compliance officer june   eventide funds announces  results provides outlook for  march   eventide hires ultra high net worth sales veteran as head of distribution december   eventide healthcare  life sciences fund named wall street journal category king november   eventide launches the eventide multiasset income fund july   eventide gilead fund best performing midcap growth mutual fund for  january   eventide gilead fund named wsj category king july   eventide gilead fund and eventide healthcare  life sciences fund named wsj category kings april   eventide gilead fund wins  lipper fund award april   eventide gilead fund and eventide healthcare  life sciences fund complete calendar year  as wsj category kings january   eventide gilead fund named category king by the wall street journal for the oneyear period ending september   october   the eventide gilead fund ranks top  percent within all midcap growth funds for  year  years and  years july   eventide gilead fund announcesbr   results january   eventide gilead fund ranked  midcap growth fund by lipper and the wall street journal for the oneyear period ending november   december   eventide gilead fund named category king by the wall street journal for the oneyear period ending september   october   the eventide gilead fund reports results for fiscal year ending june   august   eventide gilead fund announces distribution partnership with multifunds february   morningstar ranks the eventide gilead fund within top decile of all midcap growth mutual funds over the three year period ending july   july   for financial advisers  q cio update july    q eventide multiasset income fund update may    q cio update april    q cio update january    special cio election update november    q cio update october    q cio update july    q eventide portfolio manager call april   portfolio manager call eventide multiasset income fund april    q eventide portfolio manager call january    q eventide portfolio manager call october   eventide introduces the multiasset income fund august    q eventide portfolio manager call july    q eventide portfolio manager call april    q eventide portfolio manager call january    q eventide portfolio manager call october    q eventide portfolio manager call july    q eventide portfolio manager call april    q eventide portfolio manager call january    qq eventide portfolio manager call october   mutual funds involve risk including the possible loss of principal past performance does not guarantee future resultsthe funds’ ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria the funds can have risk related to option investing there are special risks associated with investments in foreign companies including exposure to currency fluctuations less efficient trading markets political instability and differing auditing and legal standards because of ongoing market volatility the funds performance may be subject to substantial shortterm changes the eventide gilead fund  eventide healthcare  life sciences fund can invest in smallersized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies the funds can also have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the us food and drug administration the funds can invest in private companies private investments include various risks including but not limited to lack of liquidity capital commitment risk and valuation risk private companies may not be financially profitable and have uncertain futures subjecting them to additional risks investors in the gilead fund should be aware that companies in the technology industries have different risks including but not limited to products becoming obsolete and entrance of competing products companies in the industrial sector also carry various risks including but not limited to risk related to debt loads and intense competition investors in the eventide multiasset income fund should be aware that interest rates are at historic lows and may change at any time based on government policy in general the price of a fixed income security falls when interest rates rise a rise in interest rates may result in volatility and increased redemptions which in turn could result in the fund being forced to liquidate portfolio securities at disadvantageous prices longerterm securities may be more sensitive to changes in interest rates the intermediateterm bond portion of the fund’s portfolio may represent  to  of the fund’s portfolio with an average duration of between two and eight years the eventide multiasset income fund may invest in other funds if other funds are utilized such underlying funds are subject to investment advisory and other expenses which will be indirectly paid by the fund as a result your cost of investing in the fund will be higher than the cost of investing directly in underlying funds and may be higher than other mutual funds that do not invest in underlying funds the fund may invest directly or indirectly in “junk bonds” such securities are speculative investments that carry greater risks than higher quality debt securities there are unique risks associated with reits mlps preferred stocks convertible bonds bdcs and yieldcos that are covered in the funds prospectus and sai the fund is a new mutual fund and has a limited history of operations for investors to evaluate an investor should consider a funds investment objectives risks charges and expenses carefully before investing or sending money this and other important information can be found in the prospectus which can be obtained at wwweventidefundscom or by calling even  please read the prospectus carefully before investing eventide mutual funds are distributed by northern lights distributors llc member finra which is not affiliated with eventide asset management llc nld bostonbased firm launches eventide healthcare  life sciences fund  pe hub subscribe to pe hub wire join over  of your peers get the mustread email for pevc professionals delivered to your inbox daily — for free us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions subscribe yes no registersign in a community for professionals in private capital bostonbased firm launches eventide healthcare  life sciences fund february   by connie loizos print email share via email separate multiple email addresses with commas share send me a copy email preview to from subject look at this story on pe hub bostonbased firm launches eventide healthcare  life sciences fund eventide asset management a bostonbased investment advisory firm that is committed to biblically responsible investing has launched a new fund the eventide healthcare  life sciences the funds lead portfolio manager is finny kuruvilla who also serves as a principal at the healthcare venture capital firm clarus ventures continue reading on pe hub writes eventide asset management a bostonbased investment advisory firm that is “committed to biblically responsible investing” has launched a new fund the eventide healthcare  life sciences the fund’s lead portfolio manager is finny kuruvilla who also serves as a principal at the healthcare venture capital firm clarus ventures press release eventide asset management llc a bostonbased investment advisory firm that is committed to biblically responsible investing has launched the eventide healthcare  life sciences fund on december   the eventide healthcare  life sciences fund is a nondiversified fund that uses bottomup fundamental research to find healthcare and life sciences companies with the potential to appreciate in value as positive data is released regarding clinical trials and fda feedback and market acceptance of products the fund has four share classes etnhx  n etihx   i etahx  a and etchx  copyright healthcare and life sciences companies include those companies that derive or are expected to derive  or more of their revenue from healthcare and life science products and services including but not limited to biotechnology pharmaceuticals diagnostics life science tools medical devices healthcare information technology healthcare services synthetic biology agricultural and environmental management and pharmaceutical manufacturing products and services these companies include smaller developmentstage companies according to lead portfolio manager finny kuruvilla md phd despite revolutionary advances in biology we’ve only witnessed its nascency dr kuruvilla commented “there is what i call an ‘opportunity vacuum’ for health and life sciences as scientific understanding significantly outpaces approved treatments it the marketplace this highly addressable pipeline combined with the deepening pockets and growing appetites of large biopharma promise exciting investment opportunities well into the future” in support of this investment thesis kuruvilla cited a recent report from morgan stanley and thomson reuters indicating a widening gap between the free cash flow of large biopharma companies and the entire us smidcap biotech market capitalization in other words “large biopharma has more money to spend than there are opportunities to buy and the gap is widening not closing” said kuruvilla in addition to a compelling investment thesis investors should be attracted to the eventide healthcare  life sciences fund because of the expectation of diversification benefits in broad investment portfolios according to the morgan stanley strategy team biotechnology has the most noncorrelation of any industry group this is especially true of smallcap biotechnology companies where risks are typically more tied to companyspecific events — such as clinical trial data releases and fda feedback — than to macroeconomic forces the eventide healthcare  life sciences fund will be managed by eventide’s lead portfolio manager finny kuruvilla md phd dr kuruvilla has been primarily responsible for the daytoday management of the eventide gilead fund since its inception on july   the eventide gilead fund is a diversified mutual fund that primarily invests in small and midcap growth companies under his leadership the eventide gilead fund’s noload class has returned an annualized performance of  from july   to december   net of all fees while the sp  has returned  and the russell midcap growth index  the fund has garnered numerous awards from the wall street journal for its outperformance since inception in july  along with his role as portfolio manager at eventide dr kuruvilla also serves as principal at clarus ventures a health care venture capital firm with  billion under management he represents clarus on the board of directors of nanostring and is also a board observer for catabasis lycera tetralogic and virdante he has cared for adult and pediatric patients suffering from a wide variety of hematologic oncologic and autoimmune disorders at the brigham  women’s hospital children’s hospital boston the dana farber cancer institute the beth israel deaconess hospital and the massachusetts general hospital he has also conducted research at the broad institute of harvard and mit in medical genetics from  to  dr kuruvilla did his residency at the brigham  women’s hospital from  to  and his fellowship in transfusion medicine at harvard medical school from  to  he received his md from harvard medical school his phd in chemistry and chemical biology from harvard university his master’s degree in electrical engineering and computer science from mit and his bachelor’s degree from caltech the following table shows the gilead fund’s performance since inception —————————————————————– ———– since  year inception as of  ytd return  year annualized  return return annualized return ————————————————————————— eventide gilead fund     ————————————————————————— sp  total return index     ————————————————————————— russell midcap growth total return index     ————————————————————————— eventide gilead fund expenses ratios gross expenses  net expenses  the advisor has agreed to maintain the fund’s total annual operating expenses at  until at least october   threeyear and inception returns are annualized the performance data quoted here represents past performance current performance may be lower or higher than the performance data quoted above past performance is no guarantee of future results the investment return and principal value of an investment will fluctuate so that investor’s shares when redeemed may be worth more or less than their original cost please review the fund’s prospectus for more information regarding the fund’s fees and expenses performance shown is for noload class shares please see a prospectus for information about other share classes for performance information current to the most recent monthend please call tollfree even  the sp  is an index created by standard  poor’s corp considered to represent the performance of the stock market generally the russell midcap growth index measures the performance of the us equity midcap growth segment it includes midcap companies with higher pricetobook ratios and forecasted growth neither index is an investment product available for purchase mutual funds involve risk including the possible loss of principal both the eventide gilead fund and eventide healthcare  life sciences fund can invest in smallersized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies the funds’ ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria the eventide healthcare  life sciences fund is nondiversified and its performance largely depends on the overall condition of the healthcare sector the eventide gilead fund and eventide healthcare  life sciences fund can both have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the us food and drug administration the funds can have risk related to option investing there are special risks associated with investments in foreign companies including exposure to currency fluctuations less efficient trading markets political instability and differing auditing and legal standards the fund can have risk associated with a higher portfolio turnover which could result in higher transactional costs an investor should consider the fund’s investment objectives risks charges and expenses carefully before investing or sending money this and other important information about the eventide gilead fund can be found in the fund’s prospectus please read the prospectus carefully before investing to obtain a current prospectus please call the fund toll free at  even  you can also obtain a prospectus at wwweventidefundscom  the eventide gilead fund is distributed by northern lights distributors llc which is not affiliated with eventide asset management llc print email share via email separate multiple email addresses with commas share send me a copy email preview to from subject look at this story on pe hub bostonbased firm launches eventide healthcare  life sciences fund eventide asset management a bostonbased investment advisory firm that is committed to biblically responsible investing has launched a new fund the eventide healthcare  life sciences the funds lead portfolio manager is finny kuruvilla who also serves as a principal at the healthcare venture capital firm clarus ventures continue reading on pe hub writes sign up to our newsletter receive updates from our pe hub wire and top stories of the week newsletters first name last name email address us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions you are now subscribed to the pehub wire and top stories of the week newsletters buyouts insiderargosy group llc produces several free newsletters that are sent directly to the email you provide at registration namely pe hub wire pe hub canada wire pe hub wire top story of the week buyouts daily and vcj alert to enable us to keep providing these services free of charge we reserve the right to contact you with special invitations to sample or purchase private equityrelated products by submitting this free subscription request for any of these products you are also consenting to this communication should you ever wish to unsubscribe from a particular communication you may activate the unsubscribe mechanism at the bottom of the email this will discontinue both the special invitations mentioned previously as well as your subscription to the weekly newsletter the information you provide will be safeguarded by argosy group llcbuyouts insider the company’s subsidiaries may use it to keep you informed of relevant products and services we occasionally allow reputable companies outside of the company to mail details of products which may be of interest to you as an international group we may transfer your data on a global basis for the purposes indicated above we will never share your email or contact details with any outside company however should you have any questions please do not hesitate to contact us email protected top posts new oil and gas company native racks up  mln by iris dorbian kkr to buy nature’s bounty from carlyle by luisa beltran blackrock leads funding round for fintech platform icapital by iris dorbian platinum equity to buy united site services by luisa beltran the pe hub podcast episode two by staff report private equity jobs of the week priceline kpmg novaquest are hiring by eamon murphy the carveout curveball by pehublogger network raymond james expands team with new hire by iris dorbian eventide asset management launches the eventide healthcare  life sciences fundhomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets close in  hrs  minssp  dow  nasdaq stocks to watchintel impresses with strong quarter starbucks and mattel shares are tankingeventide asset management launches the eventide healthcare  life sciences fundmarketwirejanuary  reblogsharetweetshareboston mamarketwire  jan      eventide asset management llc a bostonbased investment advisory firm that is committed to biblically responsible investing has launched the eventide healthcare  life sciences fund  nasdaq  etglx  on december   the eventide healthcare  life sciences fund is a nondiversified fund that uses bottomup fundamental research to find healthcare and life sciences companies with the potential to appreciate in value as positive data is released regarding clinical trials and fda feedback and market acceptance of products the fund has four share classes etnhx n etihx i etahx a and etchx chealthcare and life sciences companies include those companies that derive or are expected to derive  or more of their revenue from healthcare and life science products and services including but not limited to biotechnology pharmaceuticals diagnostics life science tools medical devices healthcare information technology healthcare services synthetic biology agricultural and environmental management and pharmaceutical manufacturing products and services these companies include smaller developmentstage companiesaccording to lead portfolio manager finny kuruvilla md phd despite revolutionary advances in biology weve only witnessed its nascency dr kuruvilla commented there is what i call an opportunity vacuum for health and life sciences as scientific understanding significantly outpaces approved treatments it the marketplace this highly addressable pipeline combined with the deepening pockets and growing appetites of large biopharma promise exciting investment opportunities well into the future in support of this investment thesis kuruvilla cited a recent report from morgan stanley and thomson reuters indicating a widening gap between the free cash flow of large biopharma companies and the entire us smidcap biotech market capitalization in other words large biopharma has more money to spend than there are opportunities to buy and the gap is widening not closing said kuruvilla in addition to a compelling investment thesis investors should be attracted to the eventide healthcare  life sciences fund because of the expectation of diversification benefits in broad investment portfolios according to the morgan stanley strategy team biotechnology has the most noncorrelation of any industry group this is especially true of smallcap biotechnology companies where risks are typically more tied to companyspecific events  such as clinical trial data releases and fda feedback  than to macroeconomic forcesthe eventide healthcare  life sciences fund will be managed by eventides lead portfolio manager finny kuruvilla md phd dr kuruvilla has been primarily responsible for the daytoday management of the eventide gilead fund since its inception on july   the eventide gilead fund is a diversified mutual fund that primarily invests in small and midcap growth companies under his leadership the eventide gilead funds noload class  nasdaq  etglx  has returned an annualized performance of  from july   to december   net of all fees while the sp  has returned  and the russell midcap growth index  the fund has garnered numerous awards from the wall street journal for its outperformance since inception in july  along with his role as portfolio manager at eventide dr kuruvilla also serves as principal at clarus ventures a health care venture capital firm with  billion under management he represents clarus on the board of directors of nanostring and is also a board observer for catabasis lycera tetralogic and virdante he has cared for adult and pediatric patients suffering from a wide variety of hematologic oncologic and autoimmune disorders at the brigham  womens hospital childrens hospital boston the dana farber cancer institute the beth israel deaconess hospital and the massachusetts general hospital he has also conducted research at the broad institute of harvard and mit in medical genetics from  to  dr kuruvilla did his residency at the brigham  womens hospital from  to  and his fellowship in transfusion medicine at harvard medical school from  to  he received his md from harvard medical school his phd in chemistry and chemical biology from harvard university his masters degree in electrical engineering and computer science from mit and his bachelors degree from caltechread morethe following table shows the gilead funds performance since inception  as of  ytd return  year return  year annualized return since inception  annualized return eventide gilead fund     sp  total return index     russell midcap growth total return index     eventide gilead fund expenses ratios gross expenses  net expenses  the advisor has agreed to maintain the funds total annual operating expenses at  until at least october   threeyear and inception returns are annualized the performance data quoted here represents past performance current performance may be lower or higher than the performance data quoted above past performance is no guarantee of future results the investment return and principal value of an investment will fluctuate so that investors shares when redeemed may be worth more or less than their original cost please review the funds prospectus for more information regarding the funds fees and expenses performance shown is for noload class shares please see a prospectus for information about other share classes for performance information current to the most recent monthend please call tollfree even the sp  is an index created by standard  poors corp considered to represent the performance of the stock market generally the russell midcap growth index measures the performance of the us equity midcap growth segment it includes midcap companies with higher pricetobook ratios and forecasted growth neither index is an investment product available for purchasemutual funds involve risk including the possible loss of principal both the eventide gilead fund and eventide healthcare  life sciences fund can invest in smallersized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies the funds ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria the eventide healthcare  life sciences fund is nondiversified and its performance largely depends on the overall condition of the healthcare sector the eventide gilead fund and eventide healthcare  life sciences fund can both have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the us food and drug administration the funds can have risk related to option investing there are special risks associated with investments in foreign companies including exposure to currency fluctuations less efficient trading markets political instability and differing auditing and legal standards the fund can have risk associated with a higher portfolio turnover which could result in higher transactional costsan investor should consider the funds investment objectives risks charges and expenses carefully before investing or sending money this and other important information about the eventide gilead fund can be found in the funds prospectus please read the prospectus carefully before investing to obtain a current prospectus please call the fund toll free at  even  you can also obtain a prospectus at wwweventidefundscom the eventide gilead fund is distributed by northern lights distributors llc which is not affiliated with eventide asset management llcreblogsharetweetsharerecently viewedyour list is emptywhat to read nexttrump’s unwitting legacy could be universal health coverageyahoo financethis will be in everyones household by banyan hillsponsoredsean hannity responds to claim he ran up a  tab at trumps hotel after flying in a yearold lobster from mainebusiness insiderintel impresses with strong quarter starbucks and mattel shares are tankingyahoo financetrump rages at republicans as john mccain kills obamacare repeal billnewsweekengineer finds pattern makes millions in stocksmoney morningsponsoredamazon shares fall after profit falls way short of expectationsyahoo finance video ways to break free from your credit card debtyahoo financeus economic growth picks up in second quarter wages continue to lagreuterszuckerberg wifes ambitious secret finally exposedunewzmesponsoredwall street opens lower as amazon weighs on tech stocksreutersapple aapl to report q earnings is a beat in storezackstamra judge admits shes been worried about shannon beadors weight for some time after rhoc star gains  lbspeoplediscover it  out of  avg by k customersdiscover cardsponsoredexxon stock falls after earnings miss estimates chevron gainsyahoo finance videoinvestors yawn as us economic growth rebounds in the second quarter amazon fallsyahoo financekellyanne conway ethical disclosures discourage people from government servicejoe f conway has some legitimate competition now with scaramucci on board about who can say the dumbest thing while representing the administration looks like she just took the lead thoughjoin the conversation  k ﻿ kite pharma inc nasdaqkite lowered to hold at vetr inc  chaffey breeze daily ratings  news for kite pharma inc complete the form below to receive the latest headlines and analysts recommendationsfor kite pharma inc with our free daily email newsletter follow chaffeybreeze recent posts l brands inc lb bond prices rise  analyst tactile systems technology inc tcmd vp sells  in stock john champlin mulliken sells  shares of wayfair inc w stock state of alaska department of revenue purchases  shares of biotechne corp nasdaqtech cvb financial corporation cvbf stake increased by state of alaska department of revenue agenus inc agen stake held by fisher asset management llc vodafone group plc vod receives “hold” rating from hsbc holdings plc alphabet inc nasdaqgoogl downgraded to “hold” at zacks investment research kite pharma inc nasdaqkite lowered to hold at vetr inc stifel nicolaus raises scientific games corp nasdaqsgms price target to  qualcomm qcom given daily media impact score of  paypal holdings inc pypl shares bought by caisse de depot et placement du quebec paypal holdings inc pypl stake lowered by aureus asset management llc tractor supply company tsco stake raised by capital investment services of america inc somewhat positive media coverage somewhat likely to impact soufun holdings limited sfun share price barclays plc cuts autozone inc nyseazo price target to  paul j mitchell sells  shares of alkermes plc alks stock positive press coverage extremely unlikely to impact ecopetrol nyseec share price taitron components nasdaqtait receiving somewhat favorable press coverage study finds dxp enterprises nasdaqdxpe earns daily coverage optimism rating of  kite pharma inc nasdaqkite lowered to hold at vetr inc posted by lucas kauffman on jul th   no comments vetr lowered shares of kite pharma inc nasdaqkite from a buy rating to a hold rating in a report released on monday morning they currently have  price objective on the biopharmaceutical company’s stock several other equities analysts have also recently weighed in on kite ubs ag cut shares of kite pharma from an outperform rating to a market perform rating in a research note on monday may th maxim group cut shares of kite pharma from a buy rating to a hold rating and set a  target price on the stock in a research note on thursday july th btig research restated a hold rating on shares of kite pharma in a research note on thursday march th cowen and company restated a neutral rating and set a  target price on shares of kite pharma in a research note on tuesday may th finally canaccord genuity set a  target price on shares of kite pharma and gave the stock a buy rating in a research note on tuesday june th one analyst has rated the stock with a sell rating ten have assigned a hold rating ten have assigned a buy rating and one has issued a strong buy rating to the stock the stock currently has an average rating of buy and an average target price of  get kite pharma inc alerts shares of kite pharma kite opened at  on monday the firm has a day moving average of  and a  day moving average of  the company’s market cap is  billion kite pharma has a  month low of  and a  month high of  kite pharma nasdaqkite last issued its quarterly earnings data on monday may th the biopharmaceutical company reported  earnings per share for the quarter missing the thomson reuters’ consensus estimate of  by  kite pharma had a negative return on equity of  and a negative net margin of  the business had revenue of  million during the quarter compared to the consensus estimate of  million during the same quarter last year the company earned  eps kite pharma’s revenue for the quarter was up  on a yearoveryear basis on average analysts expect that kite pharma will post  earnings per share for the current year copyright violation notice “kite pharma inc nasdaqkite lowered to hold at vetr inc” was first published by chaffey breeze and is the sole property of of chaffey breeze if you are reading this piece on another domain it was illegally copied and reposted in violation of us and international trademark  copyright law the legal version of this piece can be read at httpswwwchaffeybreezecomkitepharmaincnasdaqkiteloweredtoholdatvetrinchtml in related news chairman arie belldegrun purchased  shares of the stock in a transaction that occurred on tuesday may th the stock was bought at an average cost of  per share for a total transaction of  following the completion of the transaction the chairman now directly owns  shares in the company valued at  the transaction was disclosed in a legal filing with the securities  exchange commission which is available at this link also coo cynthia m butitta sold  shares of the firm’s stock in a transaction on monday july th the stock was sold at an average price of  for a total value of  following the completion of the sale the chief operating officer now owns  shares of the company’s stock valued at  the disclosure for this sale can be found here over the last  days insiders purchased  shares of company stock valued at  and sold  shares valued at   of the stock is owned by company insiders a number of hedge funds have recently modified their holdings of kite winslow evans  crocker inc bought a new stake in shares of kite pharma during the second quarter worth about  baillie gifford  co bought a new stake in shares of kite pharma during the first quarter worth about  turner investments llc bought a new stake in shares of kite pharma during the first quarter worth about  opus point partners management llc bought a new stake in shares of kite pharma during the fourth quarter worth about  finally neuberger berman group llc bought a new stake in shares of kite pharma during the first quarter worth about  institutional investors own  of the company’s stock about kite pharma kite pharma inc is a clinicalstage biopharmaceutical company the company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells the company offers engineered autologous cell therapy which is an approach to the treatment of cancer its therapy involves modifying a patient’s t cells outside the patient’s body or ex vivo causing the t cells to express chimeric antigen receptors cars or t cell receptors tcrs and then reinfusing the engineered t cells back into the patient receive news  ratings for kite pharma inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for kite pharma inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website eventide asset management llc  boston  ma  company information products resources my account talk to a db advisor  business directory ma boston investment advice manager of mutual funds contract or fee basis eventide asset management llc e eventide asset management llc claim this business  international pl   boston ma  get directions   wwweventidefundscom business info founded  incorporated annual revenue  employee count  industries manager of mutual funds contract or fee basis contacts david barksdale contact business your email address subject message send message company summary eventide asset management llc was founded in  eventide asset management llc specializes in manager of mutual funds contract or fee basis verified status unverified address unverified last verified  phone unverified payment method unverified view full report similar businesses nearby our similar businesses nearby shows similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile competitive landscape our competitive landscape shows how this business compares to similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile payments accepted no data hours sunday   monday   tuesday   wednesday   thursday   friday   saturday   e view additional data select from over  networks below to view available data about this business if this data is unavailable or inaccurate and you own or represent this business click here for more information on how you may be able to correct it credibility review google facebookcom yellowbookcom bingcom yellowpagescom merchantcircle tele atlas tomtom twittercom aol mapquest yahoo local applesiri groupon hotfrogcom comcastnet search reachlocal admedia dealsplus shoptopiacom alteryx dogtime media kslcom sirtune americantownscom driverside kudzucom specialsagentcom answerscom egood lawinfocom spotlikescom anywhocom egumball likenesscom spotzot eservicelog mapmyrun technocom apartmentguidecom ezlocalcom eztousecom teleroute aroundmecom metropolistcom therapistscom atlanta newhomes findlawcom time out new york avantar findthebestcom mojopagescom bb yellowpages fivestar software mycitywaycom tripadvisor bckyrdcom giftcardscom mycouponscom beachcaliforniacom golocalcom mymovecom upmesocialcom belo goodinfo newsgazette nokia usdirectorycom carscom nomao centzycom hibu openlistcom chacha search homeplatecom ownlocalcom visikard challamacom homestore patchcom voltari citybot pelopidas vouchd classifiedads hostway placeiq walkscorecom cloudmade hoodoyou planetdiscovercom weddingwirecom powerprofiles where inc contractorscom igolocalcom radiate media wikiocity couponmap indeedcom wimgocom crowdspot innova electronics intellistrand realtorcom datasphere inthemocom replycom yellowbotcom jiwire rocket fuel yellowpagecitycom dmvorg justclicklocalcom dirxion keencom zidstercom photos business credit report receive a onetime comprehensive credit report on this company get full credit report facebook twitter yelp call  to speak with a db advisor today customer resources products education center business articles  insights glossary contact us customer support communication preferences search for db duns our company about us company history business credit history careers press releases news success stories hoovers our network partners affiliates blog access to capital entrepreneurial initiative db international supplieredge site links business directory site map pipeda privacy policy website terms of service product license agreement  dun  bradstreet inc  all rights reserved eventide asset management llc  wealthminder eventide asset management llc eventide asset management llc crd  is a financial advisory firm headquartered in boston ma they manage  in  accounts and serve the financial needs of clients across  states or territories current firm details eventide asset management llc one international place th floor boston ma   httpeventidefundscom httpeventidefundscom by the numbers total assets under management  million total number of accounts  accounts average account value  compensation options a percentage of assets under your management advisory services offered portfolio management for investment companies as well as business development companies portfolio management for businesses other than small businesses or institutional clients types of clients registered states registered investment advisor advisors affiliated with a ria are permitted to work with up to five clients in nearlyall states without explicit registration the map below shows states where this firm has explicit registration only financial advisors at eventide asset management llc no advisor found our primary data source is public filings of form adv as published by the securities and exchange commission sec and made available in accordance with the freedom of information act foia supplementary information may be provided by listed advisors or their representatives because many firms provide a variety of products or services an individual may or may not be registered to operate under all services provided by the firmdo not rely solely on the information on this page the information may be inaccurate incomplete or outdated for the most accurate and uptodate information please search for the firm or individual on the sec site at httpwwwadviserinfosecgoviapdcontentsearchiapdsearchaspx ready to hire a financial advisor get competitive proposals from multiple advisors request proposals timeout you have been idle and will be logged out in seconds stay logged in log out now tesaro nasdaqtsro stock price news  analysis  marketbeat tesaro company profile nasdaqtsro company profile analyst ratings earnings history earnings estimates dividend history insider trade headlines social media chart about tesaro nasdaqtsro tesaro inc is an oncologyfocused biopharmaceutical company the company operates through the business of developing and commercializing of oncologyfocused therapeutics segment it is developing oncologyrelated product candidates including rolapitant niraparib and the product candidates under its immunooncology platform rolapitant is a potent and longacting neurokinin receptor antagonist for the prevention of chemotherapy induced nausea and vomiting niraparib is an orally active and potent poly adenosine diphosphate adpribose polymerase inhibitor it has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers it has initiated a phase i dose escalation study for its first immunooncology antibody tsr which targets programmed cell death protein  it has commenced preclinical research for its antibody candidate targeting lymphocyteactivation gene andtsr it has commenced a phase i clinical trial of tsr industry sector and symbol sector medical industry bio therapeutic drugs subindustry biotechnology symbol nasdaqtsro cusip  web wwwtesarobiocom capitalizationmarket cap  billionoutstanding shares average prices day moving avg  day moving avg  week range    petrailing pe ratio naforeward pe ratio pe growth sales  book valueannual revenue  millionprice  sales book value  per shareprice  book  profitabilityebidta net margins return on equity return on assets debtdebttoequity ratio current ratio quick ratio miscaverage volume  million shsbeta short ratio    frequently asked questions for tesaro nasdaqtsro what is tesaros stock symbol tesaro trades on the nasdaq under the ticker symbol tsro how were tesaros earnings last quarter tesaro inc nasdaqtsro issued its quarterly earnings results on tuesday may th the company reported  earnings per share eps for the quarter missing the thomson reuters consensus estimate of  by  the company had revenue of  million for the quarter compared to analyst estimates of  million tesaro had a negative return on equity of  and a negative net margin of  the firms quarterly revenue was up  on a yearoveryear basis during the same quarter last year the company earned  eps view tesaros earnings history when will tesaro make its next earnings announcement tesaro is scheduled to release their next quarterly earnings announcement on wednesday august nd  view earnings estimates for tesaro where is tesaros stock going where will tesaros stock price be in   brokers have issued twelvemonth target prices for tesaros shares their predictions range from  to  on average they anticipate tesaros stock price to reach  in the next year view analyst ratings for tesaro what are analysts saying about tesaro stock here are some recent quotes from research analysts about tesaro stock  fbr  co analysts commented we received our first data snapshot from the rx phase a study in advanced muscle invasive bladder cancer at asco this weekend with data coming from  patients in stage  of the study the study achieved the predefined efficacy criteria two of ten patients achieving a pfs of at least four months or a partial or complete tumor response where  of patients have experienced pfs for a minimum of six months one of the two aforementioned patients is still on study achieving  days of stable disease while only stage  of this study we believe it is important to point out that patients who have reached this stage of disease are usually limited to palliative or best supportive care   cann analysts commented on saturday june   tesaro provided a corporate update that described initial data from the topacio trial of niraparib zejula plus keytruda pembrolizumab and results of a phase i trial of tsr and provided an update on the commercial launch of zejula and its commercial businesses in the us and europe the launch is exceeding our expectations and management reiterated plans to advance zejula into the frontline ovarian cancer setting and to expand into other tumor types including nonsmall cell lung cancer we are adjusting our zejula outlook based on the current status of the launch   cowen and company analysts commented tsro reported q financials provided a pipeline update and commented on zejula’s   according to zacks investment research tesaro inc is an oncologyfocused biopharmaceutical company for cancer patients the companys product portfolio consists of rolapitant a neurokinin receptor antagonist for the prevention of chemotherapy induced nausea and vomiting tsr an orally available anaplastic lymphoma kinase inhibitor for the treatment of nonsmall cell lung cancer and other cancer indications and niraparib an orally active and potent poly adpribose polymerase inhibitor for the treatment of patients with solid tumors tesaro inc is based in waltham massachusetts    wedbush analysts commented with firstmover advantage in the maintenance setting a lack of requirement for a diagnostic as well clinical data that is at least as good as lynparza in gbrca patients we continue to believe that tsro remains an attractive acquisition candidate  who are some of tesaros key competitors some companies that are related to tesaro include exelixis exel bioverativ bivv kite pharma kite bluebird bio blue neurocrine biosciences nbix clovis oncology clvs intercept pharmaceuticals icpt juno therapeutics juno ultragenyx pharmaceutical rare gw pharmaceuticals plc gwph beigene bgne agios pharmaceuticals agio china biologic products cbpo sarepta therapeutics srpt avexis avxs prothena corporation plc prta axovant sciences axon and spark therapeutics once who are tesaros key executives tesaros management team includes the folowing people david m mott independent chairman of the boardmary lynne hedley phd president chief operating officer directorleon o moulder jr chief executive officer directortimothy r pearson chief financial officer executive vice presidentjeffrey h hanke phd executive vice president  research and development chief scientific officerjoseph l farmer senior vice president general counsel secretarygrant c bogle senior vice president chief commercial officermartin h huber md senior vice president and chief medical officerlawrence m alleva independent directorjames o armitage md independent director who owns tesaro stock tesaros stock is owned by a variety of of retail and institutional investors top institutional shareholders include nea management company llc  interwest venture management co  peregrine capital management llc  spark investment management llc  creative planning  and whittier trust co  company insiders that own tesaro stock include arnold l oronsky edward c english enterprise associates  l new grant c bogle james o armitage jeffrey h hanke martin h jr huber and mary lynne hedley view institutional ownership trends for tesaro who sold tesaro stock who is selling tesaro stock tesaros stock was sold by a variety of institutional investors in the last quarter including jag capital management llc spark investment management llc russell investments group ltd peregrine capital management llc capital impact advisors llc and centurylink investment management co company insiders that have sold tesaro stock in the last year include edward c english grant c bogle jeffrey h hanke martin h jr huber and mary lynne hedley view insider buying and selling for tesaro who bought tesaro stock who is buying tesaro stock tesaros stock was acquired by a variety of institutional investors in the last quarter including creative planning oregon public employees retirement fund mn services vermogensbeheer bv great west life assurance co can bank of montreal can xact kapitalforvaltning ab sumitomo mitsui asset management company ltd and shell asset management co company insiders that have bought tesaro stock in the last two years include arnold l oronsky enterprise associates  l new and james o armitage view insider buying and selling for tesaro how do i buy tesaro stock shares of tesaro can be purchased through any online brokerage account popular online brokerages include vanguard brokerage services td ameritrade etrade scottrade fidelity and charles schwab what is tesaros stock price today one share of tesaro stock can currently be purchased for approximately  marketbeat community rating for tesaro nasdaq tsrocommunity ranking   out of    outperform votes   vote outperformunderperform votes   vote underperformtotal votes  marketbeats community ratings are surveys of what our community members think about tesaro and other stocks vote outperform if you believe the stock will outperform the sp  over the long term vote underperform if you believe the stock will underperform the sp  over the long term you may vote once every thirty days analyst ratings consensus ratings for tesaro nasdaqtsro how are consensus ratings calculated marketbeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months since brokers often use different ratings systems each rating is normalized to a standardized rating score of  sell  hold  buy or  strong buy consensus ratings scores are calculated using the mean average of the number of normalized sell hold buy and strong buy ratings each stocks consensus rating is derived from its calculated consensus ratings score   sell   hold   buy   strong buy marketbeats consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve monthsmarketbeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and marketbeat has received a report that coverage was dropped ratings from certain research firms that issue ratings using purely quantitative methods such as zacks vetr and valuengine are not included in consensus calculations marketbeats consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available dataratings breakdown  hold ratings  buy ratingsconsensus ratingbuy score consensus price target   upside analysts ratings history for tesaro nasdaqtsro show only the most recent rating from each brokerage all ratings for this stock datefirmactionratingprice targetimpact on share pricedetailscredit suisse groupset price targetbuymediumjanney montgomery scottreiterated ratingneutrallowgabelliinitiated coveragebuyhighraymond james financial increiterated ratingmarket performmediumleerink swannlower price targetmarket perform  highwells fargo  companyreiterated ratingoutperformhighbank of america corporationreiterated ratingbuyhighcowen and companylower price targetmarket perform  highwedbushreiterated ratingoutperform  highrobert w bairdreiterated ratingneutralmediumfbr  colower price targetmkt perform  mkt perform  highcannreiterated ratingbuyhighoppenheimer holdings incset price targetbuy  highjefferies group llcreiterated ratingholdlowcitigroup increiterated ratingbuy  lowpiper jaffray companiesinitiated coverageoverweight  overweightlowmorgan stanleyboost price targetoverweight  highargusinitiated coveragebuyhighroyal bank of canadaboost price targetoutperform  nasuntrust banks increiterated ratingbuy  averagenalake street capitalreiterated ratingbuy  namizuholower price targetbuy  nadata available from  forward earnings earnings history for tesaro nasdaqtsroearnings history by quarter for tesaro nasdaq tsrodatequarterconsensus estimateactual epsrevenue estimateactual revenuerelease linkconference calldetailsnaq  million millionviewlistenq million millionviewnaq million millionviewnaq million millionviewlistenq millionviewlistenqviewlistenqviewlistenqviewlistenqviewnaqviewnaqviewnaqviewnaqviewnaq viewnaq viewnaq viewnaviewnaviewnadata available from  forward estimates earnings estimates for tesaro nasdaqtsro eps consensus estimate  eps consensus estimate quarternumber of estimateslow estimatehigh estimateaverage estimateq q q q q q q q data provided by zacks investment research dividends dividend history for tesaro nasdaqtsrono dividend announcements for this company have been tracked by marketbeatcom insider trades insider trading and institutional ownership history for tesaro nasdaqtsroinsider ownership percentage insider trades by quarter for tesaro nasdaqtsrotransaction dateinsider nametitlebuysellnumber of sharesaverage share pricetotal transactiondetailsedward c englishvpsell  martin h jr hubersvpsell  edward c englishvpsell  edward c englishvpsell  grant c boglesvpsell  mary lynne hedleycoosell  martin h jr hubersvpsell  martin h jr hubersvpsell  martin h jr hubersvpsell  edward c englishvpsell  jeffrey h hankevpsell  jeffrey h hankevpsell  edward c englishvpsell  arnold l oronskydirectorbuy  enterprise associates  l newmajor shareholderbuy  edward c englishvpsell  edward c englishvpsell  james o armitagedirectorbuy  james o armitagedirectorbuy  lawrence m allevadirectorbuy  lawrence m allevadirectorbuy  peter j barrismajor shareholdersell  lawrence m allevadirectorbuy  lawrence m allevadirectorbuy  leon o moulder jrceobuy  data available from  forward headlines headline trends for tesaro nasdaqtsro latest headlines for tesaro nasdaqtsro source all sources trusted sources marketbeatcom bloomberg marketwatch motley fool nasdaq reuters seeking alpha the street the wall street journal yahoo finance dateheadlinetesaro tsro takeda enter pact for niraparib in japan  streetinsidercomwwwstreetinsidercom  july  at  amtesaro inc nasdaqtsro to release earnings on wednesdaywwwamericanbankingnewscom  july  at  amtesaro inc tsro given a  price target at credit suisse groupwwwamericanbankingnewscom  july  at  pmzacks brokerages expect tesaro inc tsro will announce quarterly sales of  millionwwwamericanbankingnewscom  july  at  pm brokerages expect tesaro inc tsro to post  epswwwamericanbankingnewscom  july  at  amsuntrust banks weighs in on tesaro incs fy earnings nasdaqtsrowwwamericanbankingnewscom  july  at  amtesaro inc nasdaqtsro given neutral rating at janney montgomery scottwwwamericanbankingnewscom  july  at  pmwall streets ma chatter from july  tesaro time frontier communications first citizens bancshares brinks   benzingawwwbenzingacom  july  at  pmtesaro inc tsro shares fall as company struggles to find buyer  investorplacecominvestorplacecom  july  at  pmtesaro inc tsro dropped on reports that sale seems unlikelywwwrttnewscom  july  at  amwall streets ma chatter from july  tesaro time frontier communications first citizens bancshares brinksmaco transportadorafeedsbenzingacom  july  at  amtesaro inc tsro shares fall as company struggles to find buyerinvestorplacecom  july  at  pmtesaro shows good potential with major approvals this yearseekingalphacom  july  at  amtesaro inc tsro is sinking on reports that sale is unlikelywwwnasdaqcom  july  at  amsale process for biotech tesaro seen unlikely to result in dealwwwcnbccom  july  at  amtesaro inc nasdaqtsro given average rating of buy by analystswwwamericanbankingnewscom  july  at  pmtesaro why gabelli sees  upside  barronswwwbarronscom  july  at  pmtesaro inc tsro now covered by gabelliwwwamericanbankingnewscom  july  at  ambidaskclub downgrades tesaro inc nasdaqtsro to sellwwwamericanbankingnewscom  june  at  pmtesaro joins ocrfa as presenting sponsor of the  ovarian cancer national conference  nasdaqwwwnasdaqcom  june  at  pmtesaro joins ocrfa as presenting sponsor of the  ovarian cancer national conferencefinanceyahoocom  june  at  pmtesaro announces lonnie moulder and mary lynne hedley named ey entrepreneurs of the year® new england  globenewswire press releaseglobenewswirecom  june  at  am analysts anticipate tesaro inc tsro will announce quarterly sales of  millionwwwamericanbankingnewscom  june  at  pmfy eps estimates for tesaro inc reduced by leerink swann tsrowwwamericanbankingnewscom  june  at  pmzacks analysts expect tesaro inc tsro to announce  earnings per sharewwwamericanbankingnewscom  june  at  amtesaro inc to post q  earnings of  per share wedbush forecasts tsrowwwamericanbankingnewscom  june  at  amtesaro inc tsro receives market perform rating from raymond james financial incwwwamericanbankingnewscom  june  at  pmtesaro inc tsro pt lowered to  at leerink swannwwwamericanbankingnewscom  june  at  amtesaro inc tsro price target cut to  by analysts at janney montgomery scottwwwamericanbankingnewscom  june  at  amtesaro inc tsro rating reiterated by cowen and companywwwamericanbankingnewscom  june  at  pmtesaro comes roaring back from much lower openfeedsbenzingacom  june  at  pmtesaro inc tsro receives consensus rating of buy from brokerageswwwamericanbankingnewscom  june  at  pmetfs with exposure to tesaro inc  june  financeyahoocom  june  at  pmleerink swann comments on tesaro incs fy earnings tsrowwwamericanbankingnewscom  june  at  pmtesaro inc breached its  day moving average in a bullish manner  tsrous  june  financeyahoocom  june  at  amwill tesaro be the focus of the next biotech bidding warwwwfoolcom  june  at  pmtodays research reports on stocks to watch gilead sciences and tesarofinanceyahoocom  june  at  amtesaro inc tsro rating reiterated by wedbushwwwamericanbankingnewscom  june  at  amwall streets ma chatter from june  neuroderm penn virginia tesaro synapticsconexantfeedsbenzingacom  june  at  amtesaros tsro outperform rating reaffirmed at wells fargo  companywwwamericanbankingnewscom  june  at  amtesaro inc tsro given a  price target by cowen and company analystswwwamericanbankingnewscom  june  at  pmtesaro inc tsro pt set at  by janney montgomery scottwwwamericanbankingnewscom  june  at  pmtesaro inc tsro given neutral rating at robert w bairdwwwamericanbankingnewscom  june  at  pmtesaro volatile after johnson  johnson suspends enrollment in prostrate cancer trial  benzingawwwbenzingacom  june  at  aminsider selling tesaro inc tsro vp sells  shares of stockwwwamericanbankingnewscom  june  at  pmtesaro announces participation at goldman sachs th annual global healthcare conferencefinanceyahoocom  june  at  amtesaro inc tsro to post q  earnings of  per share fbr  co forecastswwwamericanbankingnewscom  june  at  amq  eps estimates for tesaro inc tsro raised by analystwwwamericanbankingnewscom  june  at  amtesaro whats tearing at the stockfinanceyahoocom  june  at  ametfs with exposure to tesaro inc  june  financeyahoocom  june  at  am social chart tesaro tsro chart for friday july   this page was last updated on  by marketbeatcom staff